compound,source,modification,full_sequence,assay,receptor,cell_line,EC50_nM,fold_to_NPS,pEC50,nH,notes
hNPS,Reinscheid2005,,,CRE-luciferase,hNPSR-Asn107,,76.6,,7.116,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS,Reinscheid2005,,,CRE-luciferase,hNPSR-Ile107,,17.3,,7.762,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS,Reinscheid2005,,,CRE-luciferase,hNPSR-Asn107,,45.08,,7.346,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS,Reinscheid2005,,,CRE-luciferase,hNPSR-Ile107,,0.63,,9.201,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS,Reinscheid2005,,,MAPK,hNPSR-Asn107,,1.23,,8.91,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS,Reinscheid2005,,,MAPK,hNPSR-Ile107,,0.32,,9.495,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS,Reinscheid2005,,,cAMP,hNPSR-Asn107,,31.9,,7.496,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS,Reinscheid2005,,,cAMP,hNPSR-Ile107,,3.45,,8.462,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS(1-10),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Asn107,,776,,6.11,,
hNPS(1-10),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Ile107,,7.38,,8.132,,
hNPS(1-10),Reinscheid2005,,,Ca2+/FLIPR,mNPSR,,27.3,,7.564,,
hNPS(1-12),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Ile107,,2520,,5.599,,
hNPS(1-12),Reinscheid2005,,,Ca2+/FLIPR,mNPSR,,32.5,,7.488,,
hNPS(1-15),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Asn107,,148,,6.83,,
hNPS(1-15),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Ile107,,15.8,,7.801,,
hNPS(1-15),Reinscheid2005,,,Ca2+/FLIPR,mNPSR,,56.1,,7.251,,
hNPS(1-17),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Asn107,,27.8,,7.556,,
hNPS(1-17),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Ile107,,4.97,,8.304,,
hNPS(1-17),Reinscheid2005,,,Ca2+/FLIPR,mNPSR,,15.3,,7.815,,
hNPS(1-18),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Asn107,,10.9,,7.963,,
hNPS(1-18),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Ile107,,2.59,,8.587,,
hNPS(1-18),Reinscheid2005,,,Ca2+/FLIPR,mNPSR,,7.85,,8.105,,
hNPS(1-20),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Asn107,,8.43,,8.074,,
hNPS(1-20),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Ile107,,1.78,,8.75,,
hNPS(1-20),Reinscheid2005,,,Ca2+/FLIPR,mNPSR,,4.66,,8.332,,
mNPS(1-20),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Asn107,,2.8,,8.553,,
mNPS(1-20),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Ile107,,0.77,,9.114,,
mNPS(1-20),Reinscheid2005,,,Ca2+/FLIPR,mNPSR,,0.99,,9.004,,
rNPS(1-10),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Asn107,,2090,,5.68,,
rNPS(1-10),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Ile107,,18.8,,7.726,,
rNPS(1-10),Reinscheid2005,,,Ca2+/FLIPR,mNPSR,,98.4,,7.007,,
rNPS(1-20),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Asn107,,3.1,,8.509,,
rNPS(1-20),Reinscheid2005,,,Ca2+/FLIPR,hNPSR-Ile107,,0.86,,9.066,,
rNPS(1-20),Reinscheid2005,,,Ca2+/FLIPR,mNPSR,,1.11,,8.955,,
[Ala10]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),7.244,,8.14,,"lab notes: [Ala10]NPS (M10→A) is reported with pEC50 8.09 ± 0.10 and Emax 97 ± 5, with a note that there is nearly no penalty in activity."
[Ala10]NPS(1-10),Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),10,,8,,
[Ala11]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),3.162,,8.5,,"lab notes: In the old NPS mastersheet, [Ala11]NPS (K11→A) has Ca2+ assay results reported: pEC50 7.78 ± 0.10 with Emax 96 ± 5%. The entry cites Del Zoppo Luisa 2010 and shows no PK or in vivo notes."
[Ala12]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),2.818,,8.55,,"lab notes: Alanine scan notes list [Ala12]NPS (K12→A) as well-tolerated and nearly as potent, with pEC50 7.95 ± 0.16 and Emax 97 ± 5."
[Ala13]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),4.169,,8.38,,"lab notes: In the alanine scan, the Thr13→Ala13 variant ([Ala13]NPS) is noted as well-tolerated and nearly as potent. The [Ala13]NPS entry reports pEC50 Ca²⁺ 8.01 ± 0.13 with Emax 95 ± 9."
[Ala14]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),4.467,,8.35,,"lab notes: [Ala14]NPS (S14→A) shows Ca2+ pEC50 7.92 ± 0.12 and Emax 105 ± 12, with the note “Highest Emax” (Del Zoppo Luisa 2010)."
[Ala15]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),5.754,,8.24,,"lab notes: In the old NPS mastersheet, [Ala15]NPS (F15→A) is reported with pEC₅₀ Ca²⁺ 7.97 ± 0.15 and Emax Ca 103 ± 18, referenced to Del Zoppo Luisa 2010."
[Ala16]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),11.482,,7.94,,"lab notes: In the old NPS mastersheet, [Ala16]NPS (Q16→A) reports a Ca²⁺ pEC50 of 7.99 ± 0.19 with Emax 92 ± 4%, referenced to Del Zoppo Luisa 2010, and no in vivo/PK/cAMP notes are listed."
[Ala17]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),4.898,,8.31,,"lab notes: [Ala17]NPS (R17→A) is listed with Ca²⁺ pEC₅₀ 7.90 ± 0.19 and Emax 87 ± 4, attributed to Del Zoppo Luisa 2010. No additional cAMP, PK, in vivo, or other notes are recorded for this entry."
[Ala18]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),5.012,,8.3,,"lab notes: [Ala18]NPS is listed as a control (native Ala; A18→A no change) with Ca²⁺ assay results pEC50 8.03 ± 0.09 and Emax 95 ± 5, referenced to Del Zoppo Luisa 2010."
[Ala19]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),6.31,,8.2,,"lab notes: [Ala19]NPS (K19→A) is listed in the old NPS mastersheet with Ca2+ pEC50 7.98 ± 0.07 and Emax 94 ± 9, referenced to Del Zoppo Luisa 2010."
[Ala1]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),3.715,,8.43,,"lab notes: In the alanine-scan data, [Ala1]NPS (S¹→A) shows a Ca²⁺ pEC50 of 7.79 ± 0.09 with Emax 85 ± 4."
[Ala3]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),138.038,,6.86,,
[Ala5]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),21.878,,7.66,,"lab notes: In the old NPS mastersheet, [Ala5]NPS (G5→A) reports Ca²⁺ assay pEC50 7.51 ± 0.13 with Emax 89 ± 9, attributed to Del Zoppo Luisa 2010, and no additional PK or in vivo notes are listed."
[Ala8]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),28.84,,7.54,,lab notes: [Ala8]NPS (T8->A) reports pEC50 Ca2+ 8.02 +/- 0.13 and Emax Ca 93 +/- 11 in the alanine scan (Del Zoppo Luisa 2010). No additional experimental notes are listed beyond a dash.
[Ala8]NPS(1-10),Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),23.442,,7.63,,
[Ala9]NPS,Roth2006,Ala substitution,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),10.471,,7.98,,"lab notes: [Ala9]NPS (G9→A) was tested in a Ca2+ assay with pEC50 8.11 ± 0.12 and Emax 96 ± 7, referenced to Del Zoppo Luisa 2010, with no additional notes recorded."
[D-Arg17]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),7.943,,8.1,,
[D-Arg3]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),93.325,,7.03,,
[D-Asn4]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),75.858,,7.12,,"lab notes: In the D-scan, [D-Asn4]NPS (listed as NPSv9.1, SFR(D-Asn)GVGTGMKKTSFQRAKS) showed about a 10× potency drop (pEC50 ~7 vs 8 for NPSv1) reported from Del Zoppo Luisa 2010."
[D-Gln16]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),17.783,,7.75,,
[D-Lys11]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),12.589,,7.9,,
[D-Lys12]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),12.882,,7.89,,"lab notes: In the NPSv10.3 entry (sequence SFRNGVGTGMK(D-Lys)TSFQRAKS, i.e., D‑Lys12), an existing D‑scan reports it is well‑tolerated with about a 2× potency drop (pEC50 7.85 vs 8.1 for NPSv1; Del Zoppo Luisa 2010). The 2025‑01‑06 NPS FLIPR and IP1 tables list NPSv10.3 with EC50 3.54 nM (fold 0.683 vs NPS) and 0.71 nM (fold 0.24 vs NPS), respectively."
[D-Lys19]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),10.233,,7.99,,
[D-Met10]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),17.378,,7.76,,
[D-Phe15]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),8.318,,8.08,,
[D-Phe2]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),309.03,,6.51,,
[D-Ser14]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),8.913,,8.05,,
[D-Ser1]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),8.128,,8.09,,"lab notes: NPSv5.2 (D-Ser1 + C16-palm) is noted as waking in mice, with FLIPR positive_fold 2.40x, IP1 positive_fold 23.53x, cAMP positive_fold 227.27x, and FLIPR Emax 81.2% (partial agonist)."
[D-Ser20]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),11.749,,7.93,,
[D-Thr13]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),13.49,,7.87,,"lab notes: The [D‑Thr13]NPS entry (listed as NPSv10.1 with Thr13→D‑Thr) reports in the existing D‑scan that the substitution was well‑tolerated but showed about a 2× potency drop, with pEC50 7.75 ± 0.17 versus 8.1 for NPSv1 (Del Zoppo Luisa 2010)."
[D-Thr8]NPS,Roth2006,D-amino acid,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),28.84,,7.54,,
hNPS,Roth2006,,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),2.884,,8.54,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS,Roth2006,,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),11.482,,7.94,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS(1-10),Roth2006,C-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),4.786,,8.32,,
hNPS(1-10),Roth2006,truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),6.026,,8.22,,
hNPS(1-10),Roth2006,reference,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),5.888,,8.23,,
hNPS(1-11),Roth2006,C-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),26.915,,7.57,,
hNPS(1-12),Roth2006,C-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),30.903,,7.51,,
hNPS(1-13),Roth2006,C-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),18.621,,7.73,,
hNPS(1-14),Roth2006,C-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),22.909,,7.64,,
hNPS(1-15),Roth2006,C-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),19.953,,7.7,,
hNPS(1-16),Roth2006,C-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),16.982,,7.77,,
hNPS(1-17),Roth2006,C-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),14.791,,7.83,,
hNPS(1-18),Roth2006,C-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),6.31,,8.2,,
hNPS(1-19),Roth2006,C-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),4.467,,8.35,,
hNPS(1-20),Roth2006,C-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),5.129,,8.29,,
hNPS(1-8),Roth2006,truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),46.774,,7.33,,
hNPS(1-9),Roth2006,truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),16.982,,7.77,,
hNPS(2-20),Roth2006,N-term truncation,,Ca2+/FLIPR,hNPSR,HEK293-hNPSR (clone 6),15.849,,7.8,,
NPS,DelZoppo2012,,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,2.239,,8.65,,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,DelZoppo2012,,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,4.786,,8.32,,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
[Aib1]NPS,DelZoppo2012,Aib substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,6.761,,8.17,,
[Aib5]NPS,DelZoppo2012,Aib substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,190.546,,6.72,,partial agonist
[Aib9]NPS,DelZoppo2012,Aib substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,10.233,,7.99,,
[Ala13]NPS,DelZoppo2012,Ala substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,19.055,,7.72,,"lab notes: In the alanine scan, the Thr13→Ala13 variant ([Ala13]NPS) is noted as well-tolerated and nearly as potent. The [Ala13]NPS entry reports pEC50 Ca²⁺ 8.01 ± 0.13 with Emax 95 ± 9."
[Ala1]NPS,DelZoppo2012,Ala substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,26.303,,7.58,,"lab notes: In the alanine-scan data, [Ala1]NPS (S¹→A) shows a Ca²⁺ pEC50 of 7.79 ± 0.09 with Emax 85 ± 4."
[Ala5]NPS,DelZoppo2012,Ala substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,24.547,,7.61,,"lab notes: In the old NPS mastersheet, [Ala5]NPS (G5→A) reports Ca²⁺ assay pEC50 7.51 ± 0.13 with Emax 89 ± 9, attributed to Del Zoppo Luisa 2010, and no additional PK or in vivo notes are listed."
"[Ala9,13]NPS",DelZoppo2012,Ala substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,15.136,,7.82,,
[Ala9]NPS,DelZoppo2012,Ala substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,23.442,,7.63,,"lab notes: [Ala9]NPS (G9→A) was tested in a Ca2+ assay with pEC50 8.11 ± 0.12 and Emax 96 ± 7, referenced to Del Zoppo Luisa 2010, with no additional notes recorded."
[Cys5]NPS,DelZoppo2012,L-amino acid sub,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,13.804,,7.86,,
[D-Ala5]NPS,DelZoppo2012,D-Ala substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,28.184,,7.55,,"partial agonist
lab notes: A note cites that substituting Gly5 with D-Ala in NPS produced an analogue with only a slight reduction in potency compared to natural NPS. It also notes that [D-Ala5]NPS behaves as a partial agonist at NPSR with about half the efficacy of NPS."
[D-Ala7]NPS,DelZoppo2012,D-Ala substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,23.442,,7.63,,
[D-Ala9]NPS,DelZoppo2012,D-Ala substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,21.38,,7.67,,
[D-Cys5]NPS,DelZoppo2012,D-amino acid sub,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,70.795,,7.15,,"partial agonist + antagonist
lab notes: The entry for [D-Cys5]NPS (Gly5→D-Cys) reports pEC50 (Ca2+) 7.15 and notes it as a partial agonist with Emax ≈ 59% and pKB 7.84, citing 10.1021/jm8012294 / 19113861."
[D-Leu5]NPS,DelZoppo2012,D-amino acid sub,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,89.125,,7.05,,"partial agonist + antagonist
lab notes: In the NPS mastersheet entry for [D‑Leu5]NPS (Gly5→D‑Leu), the Ca²⁺ assay reports pEC₅₀ 7.05, with notes calling it a partial agonist (Ca²⁺ Emax ≈ 118%) and listing pKB 7.44."
[Ipv5]NPS A,DelZoppo2012,Ipv substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,602.56,,6.22,,partial agonist + antagonist
[L-Lys5]NPS,DelZoppo2012,L-amino acid sub,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,630.957,,6.2,,partial agonist
[Leu5]NPS,DelZoppo2012,L-amino acid sub,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,229.087,,6.64,,"lab notes: In the old NPS mastersheet, [Leu5]NPS (Gly5→Leu, L‑Leu at position 5) is listed with a Ca2+ pEC50 of 6.64 and a Ca2+ Emax of approximately 214%."
[Met5]NPS,DelZoppo2012,L-amino acid sub,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,87.096,,7.06,,"lab notes: In the NPS mastersheet, the [Met5]NPS entry (Gly5→Met) lists a Ca²⁺ assay result with pEC50 7.06 and Ca²⁺ Emax ≈ 240%."
[Phe5]NPS,DelZoppo2012,L-amino acid sub,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,776.247,,6.11,,"partial agonist
lab notes: In the NPS Mastersheet, [Phe5]NPS is listed with a Ca²⁺ assay pEC₅₀ of 6.11 and a Ca²⁺ Emax of about 69%."
[Pro4]NPS,DelZoppo2012,Pro substitution,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,158.489,,6.8,,
[Val5]NPS,DelZoppo2012,L-amino acid sub,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,66.069,,7.18,,"lab notes: In the old NPS mastersheet, [Val5]NPS (Gly5→Val, L-Val at position 5) shows pEC50 Ca2+ 7.18 with Ca2+ Emax approx 231%."
hNPS,DelZoppo2012,,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,9.12,,8.04,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS,DelZoppo2012,,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,1.349,,8.87,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
hNPS,DelZoppo2012,,,Ca2+/FLIPR,mNPSR,HEK293-mNPSR,1.349,,8.87,,"lab notes: hNPS (WT) shows Ca2+ assay pEC50 ~8–8.5 (and 9.23 for NPSR 107I) with Emax 100%, cAMP pEC50 8.38 (107I) with Emax 100%, a brain homogenate t1/2 ≈ 11.8 min, and anxiolytic in vivo effects with ICV 0.1–1 nmol (rapid). Another hNPS entry reports log(t/KA) values of Gαs 6.76 ± 0.19 and Gαq 7.60 ± 0.20 (bias ≈ 1), and a separate assay table lists hNPS pEC50 7.94 ± 0.03 with Emax 100."
M-1,Li2021,gGlu-C18 at Lys19,,Ca2+/FLIPR,hNPSR,HEK293 transient hNPSR,20.654,,7.685,,"lab notes: M-1 shows pEC₅₀ Ca²⁺ 7.69, increased stability vs mNPS, and weak self-assembly."
M-2,Li2021,gGlu-C18 at Lys11,,Ca2+/FLIPR,hNPSR,HEK293 transient hNPSR,133.66,,6.874,,"lab notes: M-2 appears in the NPS lipidation notes as part of the Lys19 lipidation set, which is described as “worst” (M1, M2). It is also grouped with M-1/M-5/M-6 as γGlu‑C16 or γGlu‑C18 conjugations at positions 19 or 11, which are reported as highly detrimental for biological activity."
M-3,Li2021,gGlu-C16 at Lys12,,Ca2+/FLIPR,hNPSR,HEK293 transient hNPSR,3.404,,8.468,,"lab notes: M-3 shows a half‑life of ~525 min in brain lysate. In vivo, it produced prolonged anxiolysis with ICV 1 nmol lasting ≥4 h and intranasal 5–10 nmol dosing, with enhanced nose‑to‑brain delivery noted."
M-4,Li2021,gGlu-C18 at Lys12,,Ca2+/FLIPR,hNPSR,HEK293 transient hNPSR,13.122,,7.882,,"lab notes: M-4 is described as mNPS with γGlu‑C18 at Lys12 (stearate at Lys12), with a reported brain‑lysate half‑life of about 1200 minutes and a note that it self‑assembles. Notes also state that γGlu‑C18 at position 12 (M‑4) decreases activity, but it had a much longer half‑life."
M-5,Li2021,gGlu-C16 at Lys11,,Ca2+/FLIPR,hNPSR,HEK293 transient hNPSR,11.776,,7.929,,"lab notes: M‑5 is described as mNPS with γ‑Glu‑C16 (palmitate) at Lys19, and the table notes increased stability. A separate note states that conjugation of γGlu‑C16 at position 19 (M‑5) is highly detrimental for biological activity."
M-6,Li2021,gGlu-C16 at Lys19,,Ca2+/FLIPR,hNPSR,HEK293 transient hNPSR,10.864,,7.964,,"lab notes: In the NPS mastersheet, M‑6 (mNPS with γ‑Glu‑C18 at Lys11 and Lys19; dual stearate) has a reported Ca²⁺ pEC50 of 7.96 with a note of increased stability. A separate note citing prior work states that conjugation at positions 19 and 11 (including M‑6) is highly detrimental for biological activity."
mNPS,Li2021,,,Ca2+/FLIPR,hNPSR,HEK293 transient hNPSR,5,,8.301,,"mNPS sequence = SFRNGVGTGMKKTSFQRAKS (same as hNPS)
lab notes: For mNPS (mouse), notes list a HEK293-hNPSR assay and report anxiolytic effects with ICV dosing at 0.1-1 nmol. The same entry notes a half-life of about 11.8 minutes."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Ile107,HEK293,4.812,1,8.318,,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Ile107,HEK293,4.582,1,8.339,,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Ile107,HEK293,3.67399994486186,1,8.435,1.097,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Ile107,HEK293,5.19239402480141,5.19239402480141,8.285,2.433,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Ile107,HEK293,6.381321709404907,5.19239402480141,8.195,2.186,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Ile107,HEK293,7.940543308528499,5.19239402480141,8.1,2.288,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Ile107,HEK293,6.55503898046819,6.55503898046819,8.183,2.002,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Ile107,HEK293,7.82380309172244,6.55503898046819,8.107,1.338,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Ile107,HEK293,7.640489590343689,6.55503898046819,8.117,1.623,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.084702494130513,1,8.681,1.114,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.513955500605384,1,8.6,0.981,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.591132300754829,1,8.587,0.921,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.760948154500392,1,8.559,0.954,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.792432000048883,1,8.554,1.163,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.329833077471188,1,8.633,0.716,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,Ca2+/FLIPR,hNPSR-Ile107,HEK293,5.305750566017314,1,8.275,1.606,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Ile107,HEK293,3.07,1,8.513,,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Ile107,HEK293,3.74,1,8.427,,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Ile107,HEK293,1.738862531541384,1,8.76,0.635,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Ile107,HEK293,2.933425828864755,,8.533,0.752,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Ile107,HEK293,2.374437103472511,,8.624,0.749,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Ile107,HEK293,2.934211108375106,,8.533,0.849,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Asn107,HEK293,45.86223318933011,1,7.339,1.006,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Asn107,HEK293,28.59953067271566,1,7.544,1.026,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Asn107,HEK293,55.98937886448455,1,7.252,1.149,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Asn107,HEK293,51.10147671187499,1,7.292,1.019,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Asn107,HEK293,29.97972466864334,1,7.523,0.858,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,IP1,hNPSR-Asn107,HEK293,14.10521124611604,1,7.851,0.907,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,cAMP,hNPSR-Asn107,HEK293,307.034883922337,1,6.513,1.048,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,cAMP,hNPSR-Asn107,HEK293,241.1911919433311,1,6.618,0.913,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,cAMP,hNPSR-Asn107,HEK293,262.7357306418966,1,6.58,1.03,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,cAMP,hNPSR-Asn107,HEK293,220.2983973900928,1,6.657,0.897,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPS,In-house,Native hNPS (WT),,cAMP,hNPSR-Asn107,HEK293,204.7397762062732,1,6.689,0.898,"plates=5; Z'=0.603
lab notes: On 2026-01-06 an AXN NPSR FLIPR 107I assay recorded AMEN v1 (ChinaPeptide) with top dose 40 nM, EC50 34.43 nM, and 4.336-fold versus NPS."
NPSv2,In-house,"C16-palm at Lys12 (γGlu linker), C-term amide, acetate salt",H-SFRNGVGTGMKK(γ-E-Pal)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,3.7,0.769,8.432,,"plates=1-2; Z'=0.526
lab notes: In the January 2026 IP1/cAMP debrief, NPSv2 is reported at 164x cAMP positive_fold, and the note suggests this strong cAMP/Gs bias may be inflated because the NPS reference peptide degrades during the long incubation."
NPSv2,In-house,"C16-palm at Lys12 (γGlu linker), C-term amide, acetate salt",H-SFRNGVGTGMKK(γ-E-Pal)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,0.9662518059436965,0.3843551748274837,9.015,0.873,"plates=1-2; Z'=0.526
lab notes: In the January 2026 IP1/cAMP debrief, NPSv2 is reported at 164x cAMP positive_fold, and the note suggests this strong cAMP/Gs bias may be inflated because the NPS reference peptide degrades during the long incubation."
NPSv2,In-house,"C16-palm at Lys12 (γGlu linker), C-term amide, acetate salt",H-SFRNGVGTGMKK(γ-E-Pal)TSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.16,0.052,9.796,,"plates=1-2; Z'=0.526
lab notes: In the January 2026 IP1/cAMP debrief, NPSv2 is reported at 164x cAMP positive_fold, and the note suggests this strong cAMP/Gs bias may be inflated because the NPS reference peptide degrades during the long incubation."
NPSv2,In-house,"C16-palm at Lys12 (γGlu linker), C-term amide, acetate salt",H-SFRNGVGTGMKK(γ-E-Pal)TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,0.7117819489559577,0.02488788914410429,9.148,1.368,"plates=1-2; Z'=0.526
lab notes: In the January 2026 IP1/cAMP debrief, NPSv2 is reported at 164x cAMP positive_fold, and the note suggests this strong cAMP/Gs bias may be inflated because the NPS reference peptide degrades during the long incubation."
NPSv2,In-house,"C16-palm at Lys12 (γGlu linker), C-term amide, acetate salt",H-SFRNGVGTGMKK(γ-E-Pal)TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,1.886626239240705,0.007822119141415312,8.724,1.111,"plates=1-2; Z'=0.526
lab notes: In the January 2026 IP1/cAMP debrief, NPSv2 is reported at 164x cAMP positive_fold, and the note suggests this strong cAMP/Gs bias may be inflated because the NPS reference peptide degrades during the long incubation."
NPSv2.1,In-house,"C8 at Lys11 (γGlu), C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGMK[γ-E-C8]K[γ-E-Pal]-TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,7.983,1.659,8.098,,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I with NPSv2.1 reported ~3× higher potency than natural NPS. Notes also say potency was similar in IP1."
NPSv2.1,In-house,"C8 at Lys11 (γGlu), C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGMK[γ-E-C8]K[γ-E-Pal]-TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,5.138588093356734,2.044025080045894,8.289,1.455,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I with NPSv2.1 reported ~3× higher potency than natural NPS. Notes also say potency was similar in IP1."
NPSv2.1,In-house,"C8 at Lys11 (γGlu), C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGMK[γ-E-C8]K[γ-E-Pal]-TSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.23,0.076,9.638,,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I with NPSv2.1 reported ~3× higher potency than natural NPS. Notes also say potency was similar in IP1."
NPSv2.1,In-house,"C8 at Lys11 (γGlu), C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGMK[γ-E-C8]K[γ-E-Pal]-TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,6.36100367919761,0.2224163659184133,8.196,1.169,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I with NPSv2.1 reported ~3× higher potency than natural NPS. Notes also say potency was similar in IP1."
NPSv2.1,In-house,"C8 at Lys11 (γGlu), C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGMK[γ-E-C8]K[γ-E-Pal]-TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,14.98671919503779,0.06213626241607936,7.824,1.104,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I with NPSv2.1 reported ~3× higher potency than natural NPS. Notes also say potency was similar in IP1."
NPSv2.2,In-house,"N-Me-Lys11, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGM-(N-Me-K)-K[γ-E-Pal]TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,1.411,0.293,8.85,,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I using NPSv2.2 reported ~3× higher potency than natural NPS, with similar potency in IP1."
NPSv2.2,In-house,"N-Me-Lys11, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGM-(N-Me-K)-K[γ-E-Pal]TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.379610735405391,0.5487808893487448,8.86,0.874,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I using NPSv2.2 reported ~3× higher potency than natural NPS, with similar potency in IP1."
NPSv2.2,In-house,"N-Me-Lys11, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGM-(N-Me-K)-K[γ-E-Pal]TSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.17,0.054,9.77,,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I using NPSv2.2 reported ~3× higher potency than natural NPS, with similar potency in IP1."
NPSv2.2,In-house,"N-Me-Lys11, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGM-(N-Me-K)-K[γ-E-Pal]TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,1.629523447539857,0.05697727931928773,8.788,1.121,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I using NPSv2.2 reported ~3× higher potency than natural NPS, with similar potency in IP1."
NPSv2.2,In-house,"N-Me-Lys11, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGM-(N-Me-K)-K[γ-E-Pal]TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,3.80382512213889,0.01577099516566349,8.42,1.153,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I using NPSv2.2 reported ~3× higher potency than natural NPS, with similar potency in IP1."
NPSv2.3,In-house,"HomoLys11, C16-palm at Lys12 (γGlu), Aib13, C-term amide, acetate",H-SFRNGVGTGM-(HomoK)-K[γ-E-Pal]-(Aib)-SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.993,0.622,8.524,,plate=AXN251121FP1; summary-only (no curve fit params)
NPSv2.3,In-house,"HomoLys11, C16-palm at Lys12 (γGlu), Aib13, C-term amide, acetate",H-SFRNGVGTGM-(HomoK)-K[γ-E-Pal]-(Aib)-SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.142842094187272,0.8523786891499295,8.669,0.852,plates=1-2; Z'=0.665
NPSv2.3,In-house,"HomoLys11, C16-palm at Lys12 (γGlu), Aib13, C-term amide, acetate",H-SFRNGVGTGM-(HomoK)-K[γ-E-Pal]-(Aib)-SFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.18,0.058,9.745,,plate=AXN251121P1; summary-only (no curve fit params)
NPSv2.3,In-house,"HomoLys11, C16-palm at Lys12 (γGlu), Aib13, C-term amide, acetate",H-SFRNGVGTGM-(HomoK)-K[γ-E-Pal]-(Aib)-SFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,1.020779455021135,0.03569217504659866,8.991,1.262,plates=1-2; Z'=0.766
NPSv2.3,In-house,"HomoLys11, C16-palm at Lys12 (γGlu), Aib13, C-term amide, acetate",H-SFRNGVGTGM-(HomoK)-K[γ-E-Pal]-(Aib)-SFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,2.713336092481193,0.01124973126348122,8.566,1.41,plates=1-2; Z'=0.526
NPSv3,In-house,1-13 truncation (SFRNGVGTGMKKT),H-SFRNGVGTGMKKT-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,6.463,1.343,8.19,,plate=AXN251121FP1; summary-only (no curve fit params)
NPSv3,In-house,1-13 truncation (SFRNGVGTGMKKT),H-SFRNGVGTGMKKT-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.664094933561813,1.059722390837974,8.574,0.876,plates=1-2; Z'=0.665
NPSv3,In-house,1-13 truncation (SFRNGVGTGMKKT),H-SFRNGVGTGMKKT-NH2,IP1,hNPSR-Ile107,HEK293,1.13,0.367,8.947,,plate=AXN251121P1; summary-only (no curve fit params)
NPSv3,In-house,1-13 truncation (SFRNGVGTGMKKT),H-SFRNGVGTGMKKT-NH2,IP1,hNPSR-Asn107,HEK293,26.48197875828238,0.9259585082473591,7.577,1.201,plates=1-2; Z'=0.766
NPSv3,In-house,1-13 truncation (SFRNGVGTGMKKT),H-SFRNGVGTGMKKT-NH2,cAMP,hNPSR-Asn107,HEK293,35.48956790379177,0.1471428853510131,7.45,0.988,plates=1-2; Z'=0.526
NPSv3.1,In-house,"1-13 trunc + C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGMKK(γ-E-Pal)T-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,1.027,0.213,8.988,,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I reported NPS-v3.1 as about 5x more potent than NPS."
NPSv3.1,In-house,"1-13 trunc + C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGMKK(γ-E-Pal)T-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.488864661508167,0.5922398630960789,8.827,0.694,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I reported NPS-v3.1 as about 5x more potent than NPS."
NPSv3.1,In-house,"1-13 trunc + C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGMKK(γ-E-Pal)T-NH2,IP1,hNPSR-Ile107,HEK293,0.07,0.024,10.155,,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I reported NPS-v3.1 as about 5x more potent than NPS."
NPSv3.1,In-house,"1-13 trunc + C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGMKK(γ-E-Pal)T-NH2,IP1,hNPSR-Asn107,HEK293,0.8300184777583862,0.02902210135043353,9.081,1.275,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I reported NPS-v3.1 as about 5x more potent than NPS."
NPSv3.1,In-house,"1-13 trunc + C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGMKK(γ-E-Pal)T-NH2,cAMP,hNPSR-Asn107,HEK293,3.255470368236091,0.01349746788846658,8.487,1.257,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I reported NPS-v3.1 as about 5x more potent than NPS."
NPSv4,In-house,1-6 hexapeptide (SFRNGV-NH2),H-SFRNGV‑NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,6.367,1.323,8.196,,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay using NPSv4 on NPSR-107I showed a 1.3× potency loss versus NPS, noted as less than expected."
NPSv4,In-house,1-6 hexapeptide (SFRNGV-NH2),H-SFRNGV‑NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,16.48546918012764,6.557581936576756,7.783,0.944,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay using NPSv4 on NPSR-107I showed a 1.3× potency loss versus NPS, noted as less than expected."
NPSv4,In-house,1-6 hexapeptide (SFRNGV-NH2),H-SFRNGV‑NH2,IP1,hNPSR-Ile107,HEK293,168.05,54.693,6.775,,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay using NPSv4 on NPSR-107I showed a 1.3× potency loss versus NPS, noted as less than expected."
NPSv4,In-house,1-6 hexapeptide (SFRNGV-NH2),H-SFRNGV‑NH2,IP1,hNPSR-Asn107,HEK293,386.4528288298227,13.51255841406181,6.413,1.182,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay using NPSv4 on NPSR-107I showed a 1.3× potency loss versus NPS, noted as less than expected."
NPSv4,In-house,1-6 hexapeptide (SFRNGV-NH2),H-SFRNGV‑NH2,cAMP,hNPSR-Asn107,HEK293,787.2938097265578,3.264189721785262,6.104,1.234,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay using NPSv4 on NPSR-107I showed a 1.3× potency loss versus NPS, noted as less than expected."
NPSv4.1,In-house,"1-7 + Lys7-C16-palm (γGlu), acetate",H-SFRNGVK(γ-E-Pal)-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,397.7795150945157,,5.157,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I reported that NPSv4.1 completely loses activity."
NPSv4.1,In-house,"1-7 + Lys7-C16-palm (γGlu), acetate",H-SFRNGVK(γ-E-Pal)-NH2,IP1,hNPSR-Ile107,HEK293,918.44,298.921,6.037,,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I reported that NPSv4.1 completely loses activity."
NPSv4.1,In-house,"1-7 + Lys7-C16-palm (γGlu), acetate",H-SFRNGVK(γ-E-Pal)-NH2,IP1,hNPSR-Asn107,HEK293,,174.828043761224,,7.889,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I reported that NPSv4.1 completely loses activity."
NPSv4.1,In-house,"1-7 + Lys7-C16-palm (γGlu), acetate",H-SFRNGVK(γ-E-Pal)-NH2,cAMP,hNPSR-Asn107,HEK293,,20.73044193576841,,-6.846,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, a cell assay on NPSR-107I reported that NPSv4.1 completely loses activity."
NPSv5,In-house,"D-Lys11, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGM-[D-Lys]-K[γ-E-Pal]-TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.018,0.419,8.695,,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, an IP1 assay lists NPS V5 at 5000 nM top dose with EC50 0.15 nM (fold to NPS 0.050). A 2025-11-21 NPSR-107I cell assay notes NPSv5 was 2.5× more potent than natural NPS and 1.8× more potent than pure NPSv2, but less potent than N‑Me‑Lys11."
NPSv5,In-house,"D-Lys11, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGM-[D-Lys]-K[γ-E-Pal]-TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,0.7996383586894386,0.3180797585704593,9.097,1.349,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, an IP1 assay lists NPS V5 at 5000 nM top dose with EC50 0.15 nM (fold to NPS 0.050). A 2025-11-21 NPSR-107I cell assay notes NPSv5 was 2.5× more potent than natural NPS and 1.8× more potent than pure NPSv2, but less potent than N‑Me‑Lys11."
NPSv5,In-house,"D-Lys11, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGM-[D-Lys]-K[γ-E-Pal]-TSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.15,0.05,9.824,,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, an IP1 assay lists NPS V5 at 5000 nM top dose with EC50 0.15 nM (fold to NPS 0.050). A 2025-11-21 NPSR-107I cell assay notes NPSv5 was 2.5× more potent than natural NPS and 1.8× more potent than pure NPSv2, but less potent than N‑Me‑Lys11."
NPSv5,In-house,"D-Lys11, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGM-[D-Lys]-K[γ-E-Pal]-TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,1.342953443810313,0.04695718468875117,8.872,1.359,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, an IP1 assay lists NPS V5 at 5000 nM top dose with EC50 0.15 nM (fold to NPS 0.050). A 2025-11-21 NPSR-107I cell assay notes NPSv5 was 2.5× more potent than natural NPS and 1.8× more potent than pure NPSv2, but less potent than N‑Me‑Lys11."
NPSv5,In-house,"D-Lys11, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-SFRNGVGTGM-[D-Lys]-K[γ-E-Pal]-TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,5.025960864726668,0.02083807797553211,8.299,1.049,"plates=1-2; Z'=0.526
lab notes: On 2025-11-21, an IP1 assay lists NPS V5 at 5000 nM top dose with EC50 0.15 nM (fold to NPS 0.050). A 2025-11-21 NPSR-107I cell assay notes NPSv5 was 2.5× more potent than natural NPS and 1.8× more potent than pure NPSv2, but less potent than N‑Me‑Lys11."
NPSv5.1,In-house,"C16-palm at Lys12 (γGlu), D-Thr13, C-term amide, acetate",H-SFRNGVGTGMK-K[γ-E-Pal]-[D-Thr]-SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.818,0.586,8.55,,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 IP1 assay (plate AXN251121P1), NPSv5.1 was tested at a 5000 nM top dose with an EC50 of 1.17 nM and a fold-to-NPS value of 0.382. A separate note reports NPSv5.1 performed roughly on par in Ca2+ assays but was substantially less potent on IP1, indicating the modification is likely not favorable right now."
NPSv5.1,In-house,"C16-palm at Lys12 (γGlu), D-Thr13, C-term amide, acetate",H-SFRNGVGTGMK-K[γ-E-Pal]-[D-Thr]-SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.732905638051786,0.6893143644087917,8.761,1.122,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 IP1 assay (plate AXN251121P1), NPSv5.1 was tested at a 5000 nM top dose with an EC50 of 1.17 nM and a fold-to-NPS value of 0.382. A separate note reports NPSv5.1 performed roughly on par in Ca2+ assays but was substantially less potent on IP1, indicating the modification is likely not favorable right now."
NPSv5.1,In-house,"C16-palm at Lys12 (γGlu), D-Thr13, C-term amide, acetate",H-SFRNGVGTGMK-K[γ-E-Pal]-[D-Thr]-SFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,1.17,0.382,8.932,,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 IP1 assay (plate AXN251121P1), NPSv5.1 was tested at a 5000 nM top dose with an EC50 of 1.17 nM and a fold-to-NPS value of 0.382. A separate note reports NPSv5.1 performed roughly on par in Ca2+ assays but was substantially less potent on IP1, indicating the modification is likely not favorable right now."
NPSv5.1,In-house,"C16-palm at Lys12 (γGlu), D-Thr13, C-term amide, acetate",H-SFRNGVGTGMK-K[γ-E-Pal]-[D-Thr]-SFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,15.2861515554438,0.5344895946151661,7.816,1.093,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 IP1 assay (plate AXN251121P1), NPSv5.1 was tested at a 5000 nM top dose with an EC50 of 1.17 nM and a fold-to-NPS value of 0.382. A separate note reports NPSv5.1 performed roughly on par in Ca2+ assays but was substantially less potent on IP1, indicating the modification is likely not favorable right now."
NPSv5.1,In-house,"C16-palm at Lys12 (γGlu), D-Thr13, C-term amide, acetate",H-SFRNGVGTGMK-K[γ-E-Pal]-[D-Thr]-SFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,42.4970930621816,0.1761967040329004,7.372,1.449,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 IP1 assay (plate AXN251121P1), NPSv5.1 was tested at a 5000 nM top dose with an EC50 of 1.17 nM and a fold-to-NPS value of 0.382. A separate note reports NPSv5.1 performed roughly on par in Ca2+ assays but was substantially less potent on IP1, indicating the modification is likely not favorable right now."
NPSv5.2,In-house,"D-Ser1, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-[D-Ser]-FRNGVGTGMK-K[γ-E-Pal]-TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,1.736581004655922,0.4726676730315564,8.76,1.001,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv5.2 was tested at a 1000 nM top dose with an EC50 of 1.74 nM (0.473-fold vs NPS). In the 2025-12-12 IP1 assay, NPSv5.2 was tested at a 5000 nM top dose with an EC50 of 0.09 nM (0.053-fold vs NPS)."
NPSv5.2,In-house,"D-Ser1, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-[D-Ser]-FRNGVGTGMK-K[γ-E-Pal]-TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,0.9688913172130945,0.3509270232524234,9.014,1.505,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv5.2 was tested at a 1000 nM top dose with an EC50 of 1.74 nM (0.473-fold vs NPS). In the 2025-12-12 IP1 assay, NPSv5.2 was tested at a 5000 nM top dose with an EC50 of 0.09 nM (0.053-fold vs NPS)."
NPSv5.2,In-house,"D-Ser1, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-[D-Ser]-FRNGVGTGMK-K[γ-E-Pal]-TSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.09292982976032983,0.05344288468735583,10.032,0.97,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv5.2 was tested at a 1000 nM top dose with an EC50 of 1.74 nM (0.473-fold vs NPS). In the 2025-12-12 IP1 assay, NPSv5.2 was tested at a 5000 nM top dose with an EC50 of 0.09 nM (0.053-fold vs NPS)."
NPSv5.2,In-house,"D-Ser1, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-[D-Ser]-FRNGVGTGMK-K[γ-E-Pal]-TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,0.598942963803017,0.01172065862558203,9.223,1.249,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv5.2 was tested at a 1000 nM top dose with an EC50 of 1.74 nM (0.473-fold vs NPS). In the 2025-12-12 IP1 assay, NPSv5.2 was tested at a 5000 nM top dose with an EC50 of 0.09 nM (0.053-fold vs NPS)."
NPSv5.2,In-house,"D-Ser1, C16-palm at Lys12 (γGlu), C-term amide, acetate",H-[D-Ser]-FRNGVGTGMK-K[γ-E-Pal]-TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,1.344498764103957,0.00610308009514563,8.871,1.223,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv5.2 was tested at a 1000 nM top dose with an EC50 of 1.74 nM (0.473-fold vs NPS). In the 2025-12-12 IP1 assay, NPSv5.2 was tested at a 5000 nM top dose with an EC50 of 0.09 nM (0.053-fold vs NPS)."
NPSv5.3,In-house,"D-Ser1, D-Lys11, C16-palm at Lys12 (γGlu), D-Thr13, C-term amide, acetate",H-[D-Ser]-FRNGVGTGM-[D-Lys]-K[γ-E-Pal]-[D-Thr]-SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.134,0.443,8.671,,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 FLIPR Ca2+ assay (plate AXN251121FP1), NPS V5.3 was tested at a 1000 nM top dose with an EC50 of 2.134 nM and a fold to NPS of 0.443. In the 2025-11-21 IP1 assay (plate AXN251121P1), NPS V5.3 was tested at a 5000 nM top dose with an EC50 of 0.62 nM and a fold to NPS of 0.202."
NPSv5.3,In-house,"D-Ser1, D-Lys11, C16-palm at Lys12 (γGlu), D-Thr13, C-term amide, acetate",H-[D-Ser]-FRNGVGTGM-[D-Lys]-K[γ-E-Pal]-[D-Thr]-SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.21449034986279,0.4830993824553893,8.916,1.202,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 FLIPR Ca2+ assay (plate AXN251121FP1), NPS V5.3 was tested at a 1000 nM top dose with an EC50 of 2.134 nM and a fold to NPS of 0.443. In the 2025-11-21 IP1 assay (plate AXN251121P1), NPS V5.3 was tested at a 5000 nM top dose with an EC50 of 0.62 nM and a fold to NPS of 0.202."
NPSv5.3,In-house,"D-Ser1, D-Lys11, C16-palm at Lys12 (γGlu), D-Thr13, C-term amide, acetate",H-[D-Ser]-FRNGVGTGM-[D-Lys]-K[γ-E-Pal]-[D-Thr]-SFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.62,0.202,9.208,,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 FLIPR Ca2+ assay (plate AXN251121FP1), NPS V5.3 was tested at a 1000 nM top dose with an EC50 of 2.134 nM and a fold to NPS of 0.443. In the 2025-11-21 IP1 assay (plate AXN251121P1), NPS V5.3 was tested at a 5000 nM top dose with an EC50 of 0.62 nM and a fold to NPS of 0.202."
NPSv5.3,In-house,"D-Ser1, D-Lys11, C16-palm at Lys12 (γGlu), D-Thr13, C-term amide, acetate",H-[D-Ser]-FRNGVGTGM-[D-Lys]-K[γ-E-Pal]-[D-Thr]-SFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,9.619795557912699,0.3363620077545579,8.017,1.11,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 FLIPR Ca2+ assay (plate AXN251121FP1), NPS V5.3 was tested at a 1000 nM top dose with an EC50 of 2.134 nM and a fold to NPS of 0.443. In the 2025-11-21 IP1 assay (plate AXN251121P1), NPS V5.3 was tested at a 5000 nM top dose with an EC50 of 0.62 nM and a fold to NPS of 0.202."
NPSv5.3,In-house,"D-Ser1, D-Lys11, C16-palm at Lys12 (γGlu), D-Thr13, C-term amide, acetate",H-[D-Ser]-FRNGVGTGM-[D-Lys]-K[γ-E-Pal]-[D-Thr]-SFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,30.31037355757739,0.1256694878173616,7.518,0.881,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 FLIPR Ca2+ assay (plate AXN251121FP1), NPS V5.3 was tested at a 1000 nM top dose with an EC50 of 2.134 nM and a fold to NPS of 0.443. In the 2025-11-21 IP1 assay (plate AXN251121P1), NPS V5.3 was tested at a 5000 nM top dose with an EC50 of 0.62 nM and a fold to NPS of 0.202."
NPSv5.4,In-house,"D-Ser1, D-Lys11, C16-palm at Lys12 (γGlu), D-Thr13, 1-13 trunc, C-term amide, acetate",H-[D-Ser]-FRNGVGTGM-[D-Lys]-K[γ-E-Pal]-[D-Thr]-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,1.309,0.272,8.883,,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 IP1 assay (plate AXN251121P1), NPS V5.4 was tested at a top dose of 5000 nM with an EC50 of 0.61 nM and a fold-to-NPS of 0.199."
NPSv5.4,In-house,"D-Ser1, D-Lys11, C16-palm at Lys12 (γGlu), D-Thr13, 1-13 trunc, C-term amide, acetate",H-[D-Ser]-FRNGVGTGM-[D-Lys]-K[γ-E-Pal]-[D-Thr]-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,3.807719074098306,1.514632646910963,8.419,1.2,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 IP1 assay (plate AXN251121P1), NPS V5.4 was tested at a top dose of 5000 nM with an EC50 of 0.61 nM and a fold-to-NPS of 0.199."
NPSv5.4,In-house,"D-Ser1, D-Lys11, C16-palm at Lys12 (γGlu), D-Thr13, 1-13 trunc, C-term amide, acetate",H-[D-Ser]-FRNGVGTGM-[D-Lys]-K[γ-E-Pal]-[D-Thr]-NH2,IP1,hNPSR-Ile107,HEK293,0.61,0.199,9.215,,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 IP1 assay (plate AXN251121P1), NPS V5.4 was tested at a top dose of 5000 nM with an EC50 of 0.61 nM and a fold-to-NPS of 0.199."
NPSv5.4,In-house,"D-Ser1, D-Lys11, C16-palm at Lys12 (γGlu), D-Thr13, 1-13 trunc, C-term amide, acetate",H-[D-Ser]-FRNGVGTGM-[D-Lys]-K[γ-E-Pal]-[D-Thr]-NH2,IP1,hNPSR-Asn107,HEK293,20.29436167309201,0.7096047101378874,7.693,1.109,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 IP1 assay (plate AXN251121P1), NPS V5.4 was tested at a top dose of 5000 nM with an EC50 of 0.61 nM and a fold-to-NPS of 0.199."
NPSv5.4,In-house,"D-Ser1, D-Lys11, C16-palm at Lys12 (γGlu), D-Thr13, 1-13 trunc, C-term amide, acetate",H-[D-Ser]-FRNGVGTGM-[D-Lys]-K[γ-E-Pal]-[D-Thr]-NH2,cAMP,hNPSR-Asn107,HEK293,156.5786831628101,0.6491890599371426,6.805,0.849,"plates=1-2; Z'=0.526
lab notes: In the 2025-11-21 IP1 assay (plate AXN251121P1), NPS V5.4 was tested at a top dose of 5000 nM with an EC50 of 0.61 nM and a fold-to-NPS of 0.199."
NPSv9.1,In-house,D-Asn4 (R3|N4 hardening),H-SFR(D-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,9.182,2.004,8.037,,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset, NPS V9.1 (AXN251121FP3) was tested at a top dose of 1000 nM with EC50 9,182 nM and fold to NPS 2,004. In the 2025‑11‑21 IP1 dataset, NPS V9.1 (AXN251121P2) was tested at a top dose of 5000 nM with EC50 9,40 nM and fold to NPS 2,512."
NPSv9.1,In-house,D-Asn4 (R3|N4 hardening),H-SFR(D-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,40,7.398,8.24,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset, NPS V9.1 (AXN251121FP3) was tested at a top dose of 1000 nM with EC50 9,182 nM and fold to NPS 2,004. In the 2025‑11‑21 IP1 dataset, NPS V9.1 (AXN251121P2) was tested at a top dose of 5000 nM with EC50 9,40 nM and fold to NPS 2,512."
NPSv9.1,In-house,D-Asn4 (R3|N4 hardening),H-SFR(D-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,5.297579511319935,2.541168116906508,8.276,0.949,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset, NPS V9.1 (AXN251121FP3) was tested at a top dose of 1000 nM with EC50 9,182 nM and fold to NPS 2,004. In the 2025‑11‑21 IP1 dataset, NPS V9.1 (AXN251121P2) was tested at a top dose of 5000 nM with EC50 9,40 nM and fold to NPS 2,512."
NPSv9.1,In-house,D-Asn4 (R3|N4 hardening),H-SFR(D-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,441.2330740127786,2.541168116906508,6.355,1.238,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset, NPS V9.1 (AXN251121FP3) was tested at a top dose of 1000 nM with EC50 9,182 nM and fold to NPS 2,004. In the 2025‑11‑21 IP1 dataset, NPS V9.1 (AXN251121P2) was tested at a top dose of 5000 nM with EC50 9,40 nM and fold to NPS 2,512."
NPSv9.1,In-house,D-Asn4 (R3|N4 hardening),H-SFR(D-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,9.4,2.512,8.027,,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset, NPS V9.1 (AXN251121FP3) was tested at a top dose of 1000 nM with EC50 9,182 nM and fold to NPS 2,004. In the 2025‑11‑21 IP1 dataset, NPS V9.1 (AXN251121P2) was tested at a top dose of 5000 nM with EC50 9,40 nM and fold to NPS 2,512."
NPSv9.1,In-house,D-Asn4 (R3|N4 hardening),H-SFR(D-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,772.4664827559175,,6.112,1.343,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset, NPS V9.1 (AXN251121FP3) was tested at a top dose of 1000 nM with EC50 9,182 nM and fold to NPS 2,004. In the 2025‑11‑21 IP1 dataset, NPS V9.1 (AXN251121P2) was tested at a top dose of 5000 nM with EC50 9,40 nM and fold to NPS 2,512."
NPSv9.1,In-house,D-Asn4 (R3|N4 hardening),H-SFR(D-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,132.8001541444865,2.895632090052312,6.877,0.902,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset, NPS V9.1 (AXN251121FP3) was tested at a top dose of 1000 nM with EC50 9,182 nM and fold to NPS 2,004. In the 2025‑11‑21 IP1 dataset, NPS V9.1 (AXN251121P2) was tested at a top dose of 5000 nM with EC50 9,40 nM and fold to NPS 2,512."
NPSv9.1,In-house,D-Asn4 (R3|N4 hardening),H-SFR(D-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,2.895632090052312,,1.399,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset, NPS V9.1 (AXN251121FP3) was tested at a top dose of 1000 nM with EC50 9,182 nM and fold to NPS 2,004. In the 2025‑11‑21 IP1 dataset, NPS V9.1 (AXN251121P2) was tested at a top dose of 5000 nM with EC50 9,40 nM and fold to NPS 2,512."
NPSv9.1,In-house,D-Asn4 (R3|N4 hardening),H-SFR(D-Asn)GVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,416.4083356787618,1.356224837905032,6.38,0.819,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset, NPS V9.1 (AXN251121FP3) was tested at a top dose of 1000 nM with EC50 9,182 nM and fold to NPS 2,004. In the 2025‑11‑21 IP1 dataset, NPS V9.1 (AXN251121P2) was tested at a top dose of 5000 nM with EC50 9,40 nM and fold to NPS 2,512."
NPSv9.1,In-house,D-Asn4 (R3|N4 hardening),H-SFR(D-Asn)GVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,1.356224837905032,,1.409,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset, NPS V9.1 (AXN251121FP3) was tested at a top dose of 1000 nM with EC50 9,182 nM and fold to NPS 2,004. In the 2025‑11‑21 IP1 dataset, NPS V9.1 (AXN251121P2) was tested at a top dose of 5000 nM with EC50 9,40 nM and fold to NPS 2,512."
NPSv9.1 ChinaPeptides,In-house,,H-SFR(D-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,,1000,,9.4,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.2,In-house,N-Me-L-Asn4 (R3|N4 hardening),H-SFR(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,762,166,6.118,,"plates=5; Z'=0.603
lab notes: On 2025-11-21 FLIPR Ca2+ (plate AXN251121FP5), NPS V9.2 was tested at 1000 nM top dose with EC50 762 nM and fold-to-NPS 166. On 2025-11-21 IP1 (plate AXN251121P2), NPS V9.2 was tested at 5000 nM top dose with EC50 2509,21 nM and fold-to-NPS 670,786."
NPSv9.2,In-house,N-Me-L-Asn4 (R3|N4 hardening),H-SFR(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,295.674344073489,141.8304745669759,6.529,4.062,"plates=5; Z'=0.603
lab notes: On 2025-11-21 FLIPR Ca2+ (plate AXN251121FP5), NPS V9.2 was tested at 1000 nM top dose with EC50 762 nM and fold-to-NPS 166. On 2025-11-21 IP1 (plate AXN251121P2), NPS V9.2 was tested at 5000 nM top dose with EC50 2509,21 nM and fold-to-NPS 670,786."
NPSv9.2,In-house,N-Me-L-Asn4 (R3|N4 hardening),H-SFR(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,7.33442970322708,3.148049435021287,8.135,1.565,"plates=5; Z'=0.603
lab notes: On 2025-11-21 FLIPR Ca2+ (plate AXN251121FP5), NPS V9.2 was tested at 1000 nM top dose with EC50 762 nM and fold-to-NPS 166. On 2025-11-21 IP1 (plate AXN251121P2), NPS V9.2 was tested at 5000 nM top dose with EC50 2509,21 nM and fold-to-NPS 670,786."
NPSv9.2,In-house,N-Me-L-Asn4 (R3|N4 hardening),H-SFR(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,7.319883436324096,1.379613184835159,8.135,6.298,"plates=5; Z'=0.603
lab notes: On 2025-11-21 FLIPR Ca2+ (plate AXN251121FP5), NPS V9.2 was tested at 1000 nM top dose with EC50 762 nM and fold-to-NPS 166. On 2025-11-21 IP1 (plate AXN251121P2), NPS V9.2 was tested at 5000 nM top dose with EC50 2509,21 nM and fold-to-NPS 670,786."
NPSv9.2,In-house,N-Me-L-Asn4 (R3|N4 hardening),H-SFR(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,2509.21,670.786,5.6,,"plates=5; Z'=0.603
lab notes: On 2025-11-21 FLIPR Ca2+ (plate AXN251121FP5), NPS V9.2 was tested at 1000 nM top dose with EC50 762 nM and fold-to-NPS 166. On 2025-11-21 IP1 (plate AXN251121P2), NPS V9.2 was tested at 5000 nM top dose with EC50 2509,21 nM and fold-to-NPS 670,786."
NPSv9.2,In-house,N-Me-L-Asn4 (R3|N4 hardening),H-SFR(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,109.0221660022272,,1.169,"plates=5; Z'=0.603
lab notes: On 2025-11-21 FLIPR Ca2+ (plate AXN251121FP5), NPS V9.2 was tested at 1000 nM top dose with EC50 762 nM and fold-to-NPS 166. On 2025-11-21 IP1 (plate AXN251121P2), NPS V9.2 was tested at 5000 nM top dose with EC50 2509,21 nM and fold-to-NPS 670,786."
NPSv9.2,In-house,N-Me-L-Asn4 (R3|N4 hardening),H-SFR(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,1343.935262468636,95.27934314622173,5.872,1.457,"plates=5; Z'=0.603
lab notes: On 2025-11-21 FLIPR Ca2+ (plate AXN251121FP5), NPS V9.2 was tested at 1000 nM top dose with EC50 762 nM and fold-to-NPS 166. On 2025-11-21 IP1 (plate AXN251121P2), NPS V9.2 was tested at 5000 nM top dose with EC50 2509,21 nM and fold-to-NPS 670,786."
NPSv9.2,In-house,N-Me-L-Asn4 (R3|N4 hardening),H-SFR(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,7.512,"plates=5; Z'=0.603
lab notes: On 2025-11-21 FLIPR Ca2+ (plate AXN251121FP5), NPS V9.2 was tested at 1000 nM top dose with EC50 762 nM and fold-to-NPS 166. On 2025-11-21 IP1 (plate AXN251121P2), NPS V9.2 was tested at 5000 nM top dose with EC50 2509,21 nM and fold-to-NPS 670,786."
NPSv9.2,In-house,N-Me-L-Asn4 (R3|N4 hardening),H-SFR(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,1589.645409931249,16.28479453580501,5.799,1.29,"plates=5; Z'=0.603
lab notes: On 2025-11-21 FLIPR Ca2+ (plate AXN251121FP5), NPS V9.2 was tested at 1000 nM top dose with EC50 762 nM and fold-to-NPS 166. On 2025-11-21 IP1 (plate AXN251121P2), NPS V9.2 was tested at 5000 nM top dose with EC50 2509,21 nM and fold-to-NPS 670,786."
NPSv9.3,In-house,D-Arg3 (R3|N4 hardening),H-SF(D-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,7.703575616361252,7.398,3.277,"plates=1-2; Z'=0.526
lab notes: In the 20250106 NPS FLIPR experiment, NPSv9.3 was tested at a 40 nM top dose with EC50 40.00 nM, with fold‑to‑NPS reported as 7.704 in one entry and 6.268 in another. In the 20250106 NPS IP1 experiment, NPSv9.3 appeared on plates AXN251223P1 and AXN251223P2 with top dose 5000 nM and EC50 values 4926,40 and 5000,00, corresponding to fold‑to‑NPS 1679,40 and 2105,76."
NPSv9.3,In-house,D-Arg3 (R3|N4 hardening),H-SF(D-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,7.703575616361252,7.398,58.527,"plates=1-2; Z'=0.526
lab notes: In the 20250106 NPS FLIPR experiment, NPSv9.3 was tested at a 40 nM top dose with EC50 40.00 nM, with fold‑to‑NPS reported as 7.704 in one entry and 6.268 in another. In the 20250106 NPS IP1 experiment, NPSv9.3 appeared on plates AXN251223P1 and AXN251223P2 with top dose 5000 nM and EC50 values 4926,40 and 5000,00, corresponding to fold‑to‑NPS 1679,40 and 2105,76."
NPSv9.3,In-house,D-Arg3 (R3|N4 hardening),H-SF(D-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,1748.307866078338,,4.518,"plates=1-2; Z'=0.526
lab notes: In the 20250106 NPS FLIPR experiment, NPSv9.3 was tested at a 40 nM top dose with EC50 40.00 nM, with fold‑to‑NPS reported as 7.704 in one entry and 6.268 in another. In the 20250106 NPS IP1 experiment, NPSv9.3 appeared on plates AXN251223P1 and AXN251223P2 with top dose 5000 nM and EC50 values 4926,40 and 5000,00, corresponding to fold‑to‑NPS 1679,40 and 2105,76."
NPSv9.3,In-house,D-Arg3 (R3|N4 hardening),H-SF(D-Arg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,4926.400152480889,,5.307,1.444,"plates=1-2; Z'=0.526
lab notes: In the 20250106 NPS FLIPR experiment, NPSv9.3 was tested at a 40 nM top dose with EC50 40.00 nM, with fold‑to‑NPS reported as 7.704 in one entry and 6.268 in another. In the 20250106 NPS IP1 experiment, NPSv9.3 appeared on plates AXN251223P1 and AXN251223P2 with top dose 5000 nM and EC50 values 4926,40 and 5000,00, corresponding to fold‑to‑NPS 1679,40 and 2105,76."
NPSv9.3,In-house,D-Arg3 (R3|N4 hardening),H-SF(D-Arg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,174.828043761224,,90.593,"plates=1-2; Z'=0.526
lab notes: In the 20250106 NPS FLIPR experiment, NPSv9.3 was tested at a 40 nM top dose with EC50 40.00 nM, with fold‑to‑NPS reported as 7.704 in one entry and 6.268 in another. In the 20250106 NPS IP1 experiment, NPSv9.3 appeared on plates AXN251223P1 and AXN251223P2 with top dose 5000 nM and EC50 values 4926,40 and 5000,00, corresponding to fold‑to‑NPS 1679,40 and 2105,76."
NPSv9.3,In-house,D-Arg3 (R3|N4 hardening),H-SF(D-Arg)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,20.73044193576841,,24.897,"plates=1-2; Z'=0.526
lab notes: In the 20250106 NPS FLIPR experiment, NPSv9.3 was tested at a 40 nM top dose with EC50 40.00 nM, with fold‑to‑NPS reported as 7.704 in one entry and 6.268 in another. In the 20250106 NPS IP1 experiment, NPSv9.3 appeared on plates AXN251223P1 and AXN251223P2 with top dose 5000 nM and EC50 values 4926,40 and 5000,00, corresponding to fold‑to‑NPS 1679,40 and 2105,76."
NPSv9.3 ChinaPeptides,In-house,,H-SF(D-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,,1000,,1.725,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.3 Noah,In-house,,H-SF(D-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,,1000,,-4.534,"Z'=0.505; 0.619; 0.668; plate_instance=1
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.3 was tested at a 40 nM top dose with an EC50 of 40.00 nM and a fold-to-NPS of 7.704."
NPSv9.4,In-house,N-Me-L-Arg3 (R3|N4 hardening),H-SF(N-Me-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,40,7.398,-1.049,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.4 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS value of 5.037."
NPSv9.4,In-house,N-Me-L-Arg3 (R3|N4 hardening),H-SF(N-Me-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,280.4001880845731,134.5036948312965,6.552,5.808,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.4 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS value of 5.037."
NPSv9.4,In-house,N-Me-L-Arg3 (R3|N4 hardening),H-SF(N-Me-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,105.4562928169503,134.5036948312965,6.977,1.951,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.4 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS value of 5.037."
NPSv9.4,In-house,N-Me-L-Arg3 (R3|N4 hardening),H-SF(N-Me-Arg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,164.8569955500808,,6.783,1.481,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.4 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS value of 5.037."
NPSv9.4,In-house,N-Me-L-Arg3 (R3|N4 hardening),H-SF(N-Me-Arg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,109.0221660022272,,-52.245,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.4 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS value of 5.037."
NPSv9.4,In-house,N-Me-L-Arg3 (R3|N4 hardening),H-SF(N-Me-Arg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,1724.999285631165,109.0221660022272,5.763,1.12,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.4 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS value of 5.037."
NPSv9.4,In-house,N-Me-L-Arg3 (R3|N4 hardening),H-SF(N-Me-Arg)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,0.159,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.4 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS value of 5.037."
NPSv9.4,In-house,N-Me-L-Arg3 (R3|N4 hardening),H-SF(N-Me-Arg)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,0.878,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.4 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS value of 5.037."
NPSv9.4 ChinaPeptides,In-house,,H-SF(N-Me-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,13.24655619733446,13.24655619733446,7.878,1.433,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.5,In-house,Orn3 (R3|N4 hardening),H-SF(Orn)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,42.738,9.327,7.369,,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset (plate AXN251121FP7), NPSv9.5 was tested at a top dose of 1000 nM with EC50 42.738 nM (fold to NPS 9.327). In the 2025‑11‑21 IP1 dataset (plate AXN251121P2), NPSv9.5 was tested at a top dose of 5000 nM with EC50 946.03 nM (fold to NPS 252.901)."
NPSv9.5,In-house,Orn3 (R3|N4 hardening),H-SF(Orn)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,9.767978093786919,9.767978093786919,8.01,6.345,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset (plate AXN251121FP7), NPSv9.5 was tested at a top dose of 1000 nM with EC50 42.738 nM (fold to NPS 9.327). In the 2025‑11‑21 IP1 dataset (plate AXN251121P2), NPSv9.5 was tested at a top dose of 5000 nM with EC50 946.03 nM (fold to NPS 252.901)."
NPSv9.5,In-house,Orn3 (R3|N4 hardening),H-SF(Orn)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,40.30787306207252,16.0336462011225,7.395,2.559,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset (plate AXN251121FP7), NPSv9.5 was tested at a top dose of 1000 nM with EC50 42.738 nM (fold to NPS 9.327). In the 2025‑11‑21 IP1 dataset (plate AXN251121P2), NPSv9.5 was tested at a top dose of 5000 nM with EC50 946.03 nM (fold to NPS 252.901)."
NPSv9.5,In-house,Orn3 (R3|N4 hardening),H-SF(Orn)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,946.03,252.901,6.024,,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset (plate AXN251121FP7), NPSv9.5 was tested at a top dose of 1000 nM with EC50 42.738 nM (fold to NPS 9.327). In the 2025‑11‑21 IP1 dataset (plate AXN251121P2), NPSv9.5 was tested at a top dose of 5000 nM with EC50 946.03 nM (fold to NPS 252.901)."
NPSv9.5,In-house,Orn3 (R3|N4 hardening),H-SF(Orn)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,248.233428838267,,6.605,1.161,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset (plate AXN251121FP7), NPSv9.5 was tested at a top dose of 1000 nM with EC50 42.738 nM (fold to NPS 9.327). In the 2025‑11‑21 IP1 dataset (plate AXN251121P2), NPSv9.5 was tested at a top dose of 5000 nM with EC50 946.03 nM (fold to NPS 252.901)."
NPSv9.5,In-house,Orn3 (R3|N4 hardening),H-SF(Orn)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,189.9563627041317,,1.054,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset (plate AXN251121FP7), NPSv9.5 was tested at a top dose of 1000 nM with EC50 42.738 nM (fold to NPS 9.327). In the 2025‑11‑21 IP1 dataset (plate AXN251121P2), NPSv9.5 was tested at a top dose of 5000 nM with EC50 946.03 nM (fold to NPS 252.901)."
NPSv9.5,In-house,Orn3 (R3|N4 hardening),H-SF(Orn)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,20.73044193576841,,1.097,"plates=1-2; Z'=0.526
lab notes: In the 2025‑11‑21 FLIPR Ca2+ dataset (plate AXN251121FP7), NPSv9.5 was tested at a top dose of 1000 nM with EC50 42.738 nM (fold to NPS 9.327). In the 2025‑11‑21 IP1 dataset (plate AXN251121P2), NPSv9.5 was tested at a top dose of 5000 nM with EC50 946.03 nM (fold to NPS 252.901)."
NPSv9.5 ChinaPeptides,In-house,,H-SF(Orn)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,52.45791579402511,52.45791579402511,7.28,1.169,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.6,In-house,Cit3 (R3|N4 hardening),H-SF(Cit)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,115.2572545229458,31.3710550497244,6.938,1.657,"plates=3-4; Z'=0.539
lab notes: 2025-12-12 FLIPR Ca2+ NPS assay lists NPSv9.6 at top dose 1000 nM with EC50 115,26 nM and fold to NPS 31,371, and the 2025-12-12 IP1 assay lists top dose 5000 nM with EC50 1373,19 nM and fold to NPS 789,7. The NPSv9.6 section notes “2025-12-12 Results: Dead agonist” and “2025-01-11 on 107N: 2x more potent?”."
NPSv9.6,In-house,Cit3 (R3|N4 hardening),H-SF(Cit)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,34.65478946767785,34.65478946767785,7.46,7.666,"plates=3-4; Z'=0.539
lab notes: 2025-12-12 FLIPR Ca2+ NPS assay lists NPSv9.6 at top dose 1000 nM with EC50 115,26 nM and fold to NPS 31,371, and the 2025-12-12 IP1 assay lists top dose 5000 nM with EC50 1373,19 nM and fold to NPS 789,7. The NPSv9.6 section notes “2025-12-12 Results: Dead agonist” and “2025-01-11 on 107N: 2x more potent?”."
NPSv9.6,In-house,Cit3 (R3|N4 hardening),H-SF(Cit)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,239.4370556618279,114.8543047921532,6.621,1.913,"plates=3-4; Z'=0.539
lab notes: 2025-12-12 FLIPR Ca2+ NPS assay lists NPSv9.6 at top dose 1000 nM with EC50 115,26 nM and fold to NPS 31,371, and the 2025-12-12 IP1 assay lists top dose 5000 nM with EC50 1373,19 nM and fold to NPS 789,7. The NPSv9.6 section notes “2025-12-12 Results: Dead agonist” and “2025-01-11 on 107N: 2x more potent?”."
NPSv9.6,In-house,Cit3 (R3|N4 hardening),H-SF(Cit)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,99.964086739168,114.8543047921532,7,2.436,"plates=3-4; Z'=0.539
lab notes: 2025-12-12 FLIPR Ca2+ NPS assay lists NPSv9.6 at top dose 1000 nM with EC50 115,26 nM and fold to NPS 31,371, and the 2025-12-12 IP1 assay lists top dose 5000 nM with EC50 1373,19 nM and fold to NPS 789,7. The NPSv9.6 section notes “2025-12-12 Results: Dead agonist” and “2025-01-11 on 107N: 2x more potent?”."
NPSv9.6,In-house,Cit3 (R3|N4 hardening),H-SF(Cit)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,1373.186738836163,789.7040242847293,5.862,1.134,"plates=3-4; Z'=0.539
lab notes: 2025-12-12 FLIPR Ca2+ NPS assay lists NPSv9.6 at top dose 1000 nM with EC50 115,26 nM and fold to NPS 31,371, and the 2025-12-12 IP1 assay lists top dose 5000 nM with EC50 1373,19 nM and fold to NPS 789,7. The NPSv9.6 section notes “2025-12-12 Results: Dead agonist” and “2025-01-11 on 107N: 2x more potent?”."
NPSv9.6,In-house,Cit3 (R3|N4 hardening),H-SF(Cit)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,414.9285885158883,,6.382,1.383,"plates=3-4; Z'=0.539
lab notes: 2025-12-12 FLIPR Ca2+ NPS assay lists NPSv9.6 at top dose 1000 nM with EC50 115,26 nM and fold to NPS 31,371, and the 2025-12-12 IP1 assay lists top dose 5000 nM with EC50 1373,19 nM and fold to NPS 789,7. The NPSv9.6 section notes “2025-12-12 Results: Dead agonist” and “2025-01-11 on 107N: 2x more potent?”."
NPSv9.6,In-house,Cit3 (R3|N4 hardening),H-SF(Cit)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,109.0221660022272,,26.999,"plates=3-4; Z'=0.539
lab notes: 2025-12-12 FLIPR Ca2+ NPS assay lists NPSv9.6 at top dose 1000 nM with EC50 115,26 nM and fold to NPS 31,371, and the 2025-12-12 IP1 assay lists top dose 5000 nM with EC50 1373,19 nM and fold to NPS 789,7. The NPSv9.6 section notes “2025-12-12 Results: Dead agonist” and “2025-01-11 on 107N: 2x more potent?”."
NPSv9.6,In-house,Cit3 (R3|N4 hardening),H-SF(Cit)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,109.0221660022272,,1.085,"plates=3-4; Z'=0.539
lab notes: 2025-12-12 FLIPR Ca2+ NPS assay lists NPSv9.6 at top dose 1000 nM with EC50 115,26 nM and fold to NPS 31,371, and the 2025-12-12 IP1 assay lists top dose 5000 nM with EC50 1373,19 nM and fold to NPS 789,7. The NPSv9.6 section notes “2025-12-12 Results: Dead agonist” and “2025-01-11 on 107N: 2x more potent?”."
NPSv9.6,In-house,Cit3 (R3|N4 hardening),H-SF(Cit)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,28.194,"plates=3-4; Z'=0.539
lab notes: 2025-12-12 FLIPR Ca2+ NPS assay lists NPSv9.6 at top dose 1000 nM with EC50 115,26 nM and fold to NPS 31,371, and the 2025-12-12 IP1 assay lists top dose 5000 nM with EC50 1373,19 nM and fold to NPS 789,7. The NPSv9.6 section notes “2025-12-12 Results: Dead agonist” and “2025-01-11 on 107N: 2x more potent?”."
NPSv9.6,In-house,Cit3 (R3|N4 hardening),H-SF(Cit)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,5.42,"plates=3-4; Z'=0.539
lab notes: 2025-12-12 FLIPR Ca2+ NPS assay lists NPSv9.6 at top dose 1000 nM with EC50 115,26 nM and fold to NPS 31,371, and the 2025-12-12 IP1 assay lists top dose 5000 nM with EC50 1373,19 nM and fold to NPS 789,7. The NPSv9.6 section notes “2025-12-12 Results: Dead agonist” and “2025-01-11 on 107N: 2x more potent?”."
NPSv9.6 ChinaPeptides,In-house,,H-SF(Cit)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,3.843036523007819,3.843036523007819,8.415,2.048,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.7,In-house,Nω-Me-Arg3 (R3|N4 hardening),H-SF(Arg(NωMe))NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,41.898,9.144,7.378,,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.7 shows an EC50 of 4.63 nM at 40 nM top dose with a fold-to-NPS of 0.725. A 2025-12-12 entry reports ~10x potency loss for NPSv9.7. A 2026-01-06 note suggests it may be more potent than NPSv1, while an IP1 note indicates ~2x potency loss."
NPSv9.7,In-house,Nω-Me-Arg3 (R3|N4 hardening),H-SF(Arg(NωMe))NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,4.628363943640734,4.628363943640734,8.335,2.232,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.7 shows an EC50 of 4.63 nM at 40 nM top dose with a fold-to-NPS of 0.725. A 2025-12-12 entry reports ~10x potency loss for NPSv9.7. A 2026-01-06 note suggests it may be more potent than NPSv1, while an IP1 note indicates ~2x potency loss."
NPSv9.7,In-house,Nω-Me-Arg3 (R3|N4 hardening),H-SF(Arg(NωMe))NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,29.60671029035954,14.20188749892004,7.529,1.042,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.7 shows an EC50 of 4.63 nM at 40 nM top dose with a fold-to-NPS of 0.725. A 2025-12-12 entry reports ~10x potency loss for NPSv9.7. A 2026-01-06 note suggests it may be more potent than NPSv1, while an IP1 note indicates ~2x potency loss."
NPSv9.7,In-house,Nω-Me-Arg3 (R3|N4 hardening),H-SF(Arg(NωMe))NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.57069564505279,14.20188749892004,8.59,1.104,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.7 shows an EC50 of 4.63 nM at 40 nM top dose with a fold-to-NPS of 0.725. A 2025-12-12 entry reports ~10x potency loss for NPSv9.7. A 2026-01-06 note suggests it may be more potent than NPSv1, while an IP1 note indicates ~2x potency loss."
NPSv9.7,In-house,Nω-Me-Arg3 (R3|N4 hardening),H-SF(Arg(NωMe))NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,29.04,7.763,7.537,,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.7 shows an EC50 of 4.63 nM at 40 nM top dose with a fold-to-NPS of 0.725. A 2025-12-12 entry reports ~10x potency loss for NPSv9.7. A 2026-01-06 note suggests it may be more potent than NPSv1, while an IP1 note indicates ~2x potency loss."
NPSv9.7,In-house,Nω-Me-Arg3 (R3|N4 hardening),H-SF(Arg(NωMe))NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,4.619858000279318,,8.335,0.475,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.7 shows an EC50 of 4.63 nM at 40 nM top dose with a fold-to-NPS of 0.725. A 2025-12-12 entry reports ~10x potency loss for NPSv9.7. A 2026-01-06 note suggests it may be more potent than NPSv1, while an IP1 note indicates ~2x potency loss."
NPSv9.7,In-house,Nω-Me-Arg3 (R3|N4 hardening),H-SF(Arg(NωMe))NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,529.9192384504938,11.55458863642471,6.276,1.625,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.7 shows an EC50 of 4.63 nM at 40 nM top dose with a fold-to-NPS of 0.725. A 2025-12-12 entry reports ~10x potency loss for NPSv9.7. A 2026-01-06 note suggests it may be more potent than NPSv1, while an IP1 note indicates ~2x potency loss."
NPSv9.7,In-house,Nω-Me-Arg3 (R3|N4 hardening),H-SF(Arg(NωMe))NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,30.74322400210751,11.55458863642471,7.512,0.983,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.7 shows an EC50 of 4.63 nM at 40 nM top dose with a fold-to-NPS of 0.725. A 2025-12-12 entry reports ~10x potency loss for NPSv9.7. A 2026-01-06 note suggests it may be more potent than NPSv1, while an IP1 note indicates ~2x potency loss."
NPSv9.7,In-house,Nω-Me-Arg3 (R3|N4 hardening),H-SF(Arg(NωMe))NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,1580.693124789684,5.148252552271918,5.801,1.222,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.7 shows an EC50 of 4.63 nM at 40 nM top dose with a fold-to-NPS of 0.725. A 2025-12-12 entry reports ~10x potency loss for NPSv9.7. A 2026-01-06 note suggests it may be more potent than NPSv1, while an IP1 note indicates ~2x potency loss."
NPSv9.7,In-house,Nω-Me-Arg3 (R3|N4 hardening),H-SF(Arg(NωMe))NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,137.6477719848111,5.148252552271918,6.861,0.727,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.7 shows an EC50 of 4.63 nM at 40 nM top dose with a fold-to-NPS of 0.725. A 2025-12-12 entry reports ~10x potency loss for NPSv9.7. A 2026-01-06 note suggests it may be more potent than NPSv1, while an IP1 note indicates ~2x potency loss."
NPSv9.7 ChinaPeptides,In-house,,H-SF(Arg(NωMe))NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,14.64805740801276,14.64805740801276,7.834,1.278,"Z'=0.505; 0.619; 0.668; plate_instance=1
lab notes: A 2026-01-06 note questions whether the NPSv9.7 result showing higher potency than NPSv1 came from an in-house prep or a vendor sample (ChinaPeptides), and in IP1 it showed ~2× potency loss. A 2025-12-12 entry reports ~10× potency loss for NPSv9.7."
NPSv9.8,In-house,"Nω,Nω'-diMe-Arg3 (R3|N4 hardening)",H-SF(Arg(NωMe2))NGVGTGMKKTSFQRAKS-NH3,Ca2+/FLIPR,hNPSR-Ile107,HEK293,41.08534780729845,11.18272956556706,7.386,1.466,"plates=3-4; Z'=0.539
lab notes: NPSv9.8 appears in the 2025-01-06 NPS FLIPR experiment (top dose 40 nM, EC50 7.74 nM, fold 1.213) and the 2025-01-06 NPS IP1 experiment (top dose 5000 nM, EC50 100.16 nM, fold 42.18). On 2025-12-12, NPSv9.8 is listed in FLIPR Ca2+ NPS (top dose 1000 nM, EC50 41.09 nM, fold 11.183) and IP1 (top dose 5000 nM, EC50 21.23 nM, fold 12.21), and a 2026-01-14 note reports plasma/CSF stability testing with ~6× worse potency on average in 107I and a recommendation to eliminate."
NPSv9.8,In-house,"Nω,Nω'-diMe-Arg3 (R3|N4 hardening)",H-SF(Arg(NωMe2))NGVGTGMKKTSFQRAKS-NH3,Ca2+/FLIPR,hNPSR-Ile107,HEK293,7.742145705622873,7.742145705622873,8.111,2.302,"plates=3-4; Z'=0.539
lab notes: NPSv9.8 appears in the 2025-01-06 NPS FLIPR experiment (top dose 40 nM, EC50 7.74 nM, fold 1.213) and the 2025-01-06 NPS IP1 experiment (top dose 5000 nM, EC50 100.16 nM, fold 42.18). On 2025-12-12, NPSv9.8 is listed in FLIPR Ca2+ NPS (top dose 1000 nM, EC50 41.09 nM, fold 11.183) and IP1 (top dose 5000 nM, EC50 21.23 nM, fold 12.21), and a 2026-01-14 note reports plasma/CSF stability testing with ~6× worse potency on average in 107I and a recommendation to eliminate."
NPSv9.8,In-house,"Nω,Nω'-diMe-Arg3 (R3|N4 hardening)",H-SF(Arg(NωMe2))NGVGTGMKKTSFQRAKS-NH3,Ca2+/FLIPR,hNPSR-Asn107,HEK293,20.22922612074336,9.703651325644222,7.694,1.349,"plates=3-4; Z'=0.539
lab notes: NPSv9.8 appears in the 2025-01-06 NPS FLIPR experiment (top dose 40 nM, EC50 7.74 nM, fold 1.213) and the 2025-01-06 NPS IP1 experiment (top dose 5000 nM, EC50 100.16 nM, fold 42.18). On 2025-12-12, NPSv9.8 is listed in FLIPR Ca2+ NPS (top dose 1000 nM, EC50 41.09 nM, fold 11.183) and IP1 (top dose 5000 nM, EC50 21.23 nM, fold 12.21), and a 2026-01-14 note reports plasma/CSF stability testing with ~6× worse potency on average in 107I and a recommendation to eliminate."
NPSv9.8,In-house,"Nω,Nω'-diMe-Arg3 (R3|N4 hardening)",H-SF(Arg(NωMe2))NGVGTGMKKTSFQRAKS-NH3,Ca2+/FLIPR,hNPSR-Asn107,HEK293,27.15711335507888,9.703651325644222,7.566,1.002,"plates=3-4; Z'=0.539
lab notes: NPSv9.8 appears in the 2025-01-06 NPS FLIPR experiment (top dose 40 nM, EC50 7.74 nM, fold 1.213) and the 2025-01-06 NPS IP1 experiment (top dose 5000 nM, EC50 100.16 nM, fold 42.18). On 2025-12-12, NPSv9.8 is listed in FLIPR Ca2+ NPS (top dose 1000 nM, EC50 41.09 nM, fold 11.183) and IP1 (top dose 5000 nM, EC50 21.23 nM, fold 12.21), and a 2026-01-14 note reports plasma/CSF stability testing with ~6× worse potency on average in 107I and a recommendation to eliminate."
NPSv9.8,In-house,"Nω,Nω'-diMe-Arg3 (R3|N4 hardening)",H-SF(Arg(NωMe2))NGVGTGMKKTSFQRAKS-NH3,IP1,hNPSR-Ile107,HEK293,21.23433563277049,12.2116241207105,7.673,0.961,"plates=3-4; Z'=0.539
lab notes: NPSv9.8 appears in the 2025-01-06 NPS FLIPR experiment (top dose 40 nM, EC50 7.74 nM, fold 1.213) and the 2025-01-06 NPS IP1 experiment (top dose 5000 nM, EC50 100.16 nM, fold 42.18). On 2025-12-12, NPSv9.8 is listed in FLIPR Ca2+ NPS (top dose 1000 nM, EC50 41.09 nM, fold 11.183) and IP1 (top dose 5000 nM, EC50 21.23 nM, fold 12.21), and a 2026-01-14 note reports plasma/CSF stability testing with ~6× worse potency on average in 107I and a recommendation to eliminate."
NPSv9.8,In-house,"Nω,Nω'-diMe-Arg3 (R3|N4 hardening)",H-SF(Arg(NωMe2))NGVGTGMKKTSFQRAKS-NH3,IP1,hNPSR-Ile107,HEK293,100.1565921641354,,6.999,1.074,"plates=3-4; Z'=0.539
lab notes: NPSv9.8 appears in the 2025-01-06 NPS FLIPR experiment (top dose 40 nM, EC50 7.74 nM, fold 1.213) and the 2025-01-06 NPS IP1 experiment (top dose 5000 nM, EC50 100.16 nM, fold 42.18). On 2025-12-12, NPSv9.8 is listed in FLIPR Ca2+ NPS (top dose 1000 nM, EC50 41.09 nM, fold 11.183) and IP1 (top dose 5000 nM, EC50 21.23 nM, fold 12.21), and a 2026-01-14 note reports plasma/CSF stability testing with ~6× worse potency on average in 107I and a recommendation to eliminate."
NPSv9.8,In-house,"Nω,Nω'-diMe-Arg3 (R3|N4 hardening)",H-SF(Arg(NωMe2))NGVGTGMKKTSFQRAKS-NH3,IP1,hNPSR-Asn107,HEK293,432.7265324456594,9.435356770771765,6.364,1.146,"plates=3-4; Z'=0.539
lab notes: NPSv9.8 appears in the 2025-01-06 NPS FLIPR experiment (top dose 40 nM, EC50 7.74 nM, fold 1.213) and the 2025-01-06 NPS IP1 experiment (top dose 5000 nM, EC50 100.16 nM, fold 42.18). On 2025-12-12, NPSv9.8 is listed in FLIPR Ca2+ NPS (top dose 1000 nM, EC50 41.09 nM, fold 11.183) and IP1 (top dose 5000 nM, EC50 21.23 nM, fold 12.21), and a 2026-01-14 note reports plasma/CSF stability testing with ~6× worse potency on average in 107I and a recommendation to eliminate."
NPSv9.8,In-house,"Nω,Nω'-diMe-Arg3 (R3|N4 hardening)",H-SF(Arg(NωMe2))NGVGTGMKKTSFQRAKS-NH3,IP1,hNPSR-Asn107,HEK293,897.3600330321602,9.435356770771765,6.047,1.155,"plates=3-4; Z'=0.539
lab notes: NPSv9.8 appears in the 2025-01-06 NPS FLIPR experiment (top dose 40 nM, EC50 7.74 nM, fold 1.213) and the 2025-01-06 NPS IP1 experiment (top dose 5000 nM, EC50 100.16 nM, fold 42.18). On 2025-12-12, NPSv9.8 is listed in FLIPR Ca2+ NPS (top dose 1000 nM, EC50 41.09 nM, fold 11.183) and IP1 (top dose 5000 nM, EC50 21.23 nM, fold 12.21), and a 2026-01-14 note reports plasma/CSF stability testing with ~6× worse potency on average in 107I and a recommendation to eliminate."
NPSv9.8,In-house,"Nω,Nω'-diMe-Arg3 (R3|N4 hardening)",H-SF(Arg(NωMe2))NGVGTGMKKTSFQRAKS-NH3,cAMP,hNPSR-Asn107,HEK293,1136.255321073125,3.700736888778199,5.945,1.214,"plates=3-4; Z'=0.539
lab notes: NPSv9.8 appears in the 2025-01-06 NPS FLIPR experiment (top dose 40 nM, EC50 7.74 nM, fold 1.213) and the 2025-01-06 NPS IP1 experiment (top dose 5000 nM, EC50 100.16 nM, fold 42.18). On 2025-12-12, NPSv9.8 is listed in FLIPR Ca2+ NPS (top dose 1000 nM, EC50 41.09 nM, fold 11.183) and IP1 (top dose 5000 nM, EC50 21.23 nM, fold 12.21), and a 2026-01-14 note reports plasma/CSF stability testing with ~6× worse potency on average in 107I and a recommendation to eliminate."
NPSv9.8,In-house,"Nω,Nω'-diMe-Arg3 (R3|N4 hardening)",H-SF(Arg(NωMe2))NGVGTGMKKTSFQRAKS-NH3,cAMP,hNPSR-Asn107,HEK293,2000.28060897949,3.700736888778199,5.699,1.196,"plates=3-4; Z'=0.539
lab notes: NPSv9.8 appears in the 2025-01-06 NPS FLIPR experiment (top dose 40 nM, EC50 7.74 nM, fold 1.213) and the 2025-01-06 NPS IP1 experiment (top dose 5000 nM, EC50 100.16 nM, fold 42.18). On 2025-12-12, NPSv9.8 is listed in FLIPR Ca2+ NPS (top dose 1000 nM, EC50 41.09 nM, fold 11.183) and IP1 (top dose 5000 nM, EC50 21.23 nM, fold 12.21), and a 2026-01-14 note reports plasma/CSF stability testing with ~6× worse potency on average in 107I and a recommendation to eliminate."
NPSv9.8 ChinaPeptides,In-house,,H-SF(Arg(NωMe2))NGVGTGMKKTSFQRAKS-NH3,Ca2+/FLIPR,hNPSR-Ile107,HEK293,113.5770902997518,113.5770902997518,6.945,2.193,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.9,In-house,Dab3 (R3|N4 hardening),H-SF(Dab)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,117.4916640972804,31.97922315202919,6.93,1.647,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv9.9 was tested at a top dose of 1000 nM with EC50 117,49 nM and fold to NPS 31,979, and in the 2025-12-12 IP1 assay (plate AXN251121P1) it had a top dose 5000 nM with EC50 4701,19 nM and fold to NPS 2704. In the 2025-01-06 NPS FLIPR assay, NPSv9.9 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 6.268, and in the 2025-01-06 NPS IP1 assay (plate AXN251223P2) it had a top dose 5000 nM with EC50 2664,45 nM and fold to NPS 1122,14."
NPSv9.9,In-house,Dab3 (R3|N4 hardening),H-SF(Dab)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,40,7.398,6.418,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv9.9 was tested at a top dose of 1000 nM with EC50 117,49 nM and fold to NPS 31,979, and in the 2025-12-12 IP1 assay (plate AXN251121P1) it had a top dose 5000 nM with EC50 4701,19 nM and fold to NPS 2704. In the 2025-01-06 NPS FLIPR assay, NPSv9.9 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 6.268, and in the 2025-01-06 NPS IP1 assay (plate AXN251223P2) it had a top dose 5000 nM with EC50 2664,45 nM and fold to NPS 1122,14."
NPSv9.9,In-house,Dab3 (R3|N4 hardening),H-SF(Dab)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,479.6847525320777,,7.103,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv9.9 was tested at a top dose of 1000 nM with EC50 117,49 nM and fold to NPS 31,979, and in the 2025-12-12 IP1 assay (plate AXN251121P1) it had a top dose 5000 nM with EC50 4701,19 nM and fold to NPS 2704. In the 2025-01-06 NPS FLIPR assay, NPSv9.9 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 6.268, and in the 2025-01-06 NPS IP1 assay (plate AXN251223P2) it had a top dose 5000 nM with EC50 2664,45 nM and fold to NPS 1122,14."
NPSv9.9,In-house,Dab3 (R3|N4 hardening),H-SF(Dab)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,466.6305140642215,479.6847525320777,6.331,2.382,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv9.9 was tested at a top dose of 1000 nM with EC50 117,49 nM and fold to NPS 31,979, and in the 2025-12-12 IP1 assay (plate AXN251121P1) it had a top dose 5000 nM with EC50 4701,19 nM and fold to NPS 2704. In the 2025-01-06 NPS FLIPR assay, NPSv9.9 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 6.268, and in the 2025-01-06 NPS IP1 assay (plate AXN251223P2) it had a top dose 5000 nM with EC50 2664,45 nM and fold to NPS 1122,14."
NPSv9.9,In-house,Dab3 (R3|N4 hardening),H-SF(Dab)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,4701.191010197381,2703.601305406295,5.328,1.735,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv9.9 was tested at a top dose of 1000 nM with EC50 117,49 nM and fold to NPS 31,979, and in the 2025-12-12 IP1 assay (plate AXN251121P1) it had a top dose 5000 nM with EC50 4701,19 nM and fold to NPS 2704. In the 2025-01-06 NPS FLIPR assay, NPSv9.9 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 6.268, and in the 2025-01-06 NPS IP1 assay (plate AXN251223P2) it had a top dose 5000 nM with EC50 2664,45 nM and fold to NPS 1122,14."
NPSv9.9,In-house,Dab3 (R3|N4 hardening),H-SF(Dab)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,2664.452369099594,,5.574,1.416,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv9.9 was tested at a top dose of 1000 nM with EC50 117,49 nM and fold to NPS 31,979, and in the 2025-12-12 IP1 assay (plate AXN251121P1) it had a top dose 5000 nM with EC50 4701,19 nM and fold to NPS 2704. In the 2025-01-06 NPS FLIPR assay, NPSv9.9 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 6.268, and in the 2025-01-06 NPS IP1 assay (plate AXN251223P2) it had a top dose 5000 nM with EC50 2664,45 nM and fold to NPS 1122,14."
NPSv9.9,In-house,Dab3 (R3|N4 hardening),H-SF(Dab)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,109.0221660022272,,-0.679,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv9.9 was tested at a top dose of 1000 nM with EC50 117,49 nM and fold to NPS 31,979, and in the 2025-12-12 IP1 assay (plate AXN251121P1) it had a top dose 5000 nM with EC50 4701,19 nM and fold to NPS 2704. In the 2025-01-06 NPS FLIPR assay, NPSv9.9 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 6.268, and in the 2025-01-06 NPS IP1 assay (plate AXN251223P2) it had a top dose 5000 nM with EC50 2664,45 nM and fold to NPS 1122,14."
NPSv9.9,In-house,Dab3 (R3|N4 hardening),H-SF(Dab)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,109.0221660022272,,1.178,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv9.9 was tested at a top dose of 1000 nM with EC50 117,49 nM and fold to NPS 31,979, and in the 2025-12-12 IP1 assay (plate AXN251121P1) it had a top dose 5000 nM with EC50 4701,19 nM and fold to NPS 2704. In the 2025-01-06 NPS FLIPR assay, NPSv9.9 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 6.268, and in the 2025-01-06 NPS IP1 assay (plate AXN251223P2) it had a top dose 5000 nM with EC50 2664,45 nM and fold to NPS 1122,14."
NPSv9.9,In-house,Dab3 (R3|N4 hardening),H-SF(Dab)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,2.373,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv9.9 was tested at a top dose of 1000 nM with EC50 117,49 nM and fold to NPS 31,979, and in the 2025-12-12 IP1 assay (plate AXN251121P1) it had a top dose 5000 nM with EC50 4701,19 nM and fold to NPS 2704. In the 2025-01-06 NPS FLIPR assay, NPSv9.9 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 6.268, and in the 2025-01-06 NPS IP1 assay (plate AXN251223P2) it had a top dose 5000 nM with EC50 2664,45 nM and fold to NPS 1122,14."
NPSv9.9,In-house,Dab3 (R3|N4 hardening),H-SF(Dab)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,-0.005,"plates=3-4; Z'=0.539
lab notes: In the 2025-12-12 FLIPR Ca2+ NPS assay, NPSv9.9 was tested at a top dose of 1000 nM with EC50 117,49 nM and fold to NPS 31,979, and in the 2025-12-12 IP1 assay (plate AXN251121P1) it had a top dose 5000 nM with EC50 4701,19 nM and fold to NPS 2704. In the 2025-01-06 NPS FLIPR assay, NPSv9.9 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 6.268, and in the 2025-01-06 NPS IP1 assay (plate AXN251223P2) it had a top dose 5000 nM with EC50 2664,45 nM and fold to NPS 1122,14."
NPSv9.9 ChinaPeptides,In-house,,H-SF(Dab)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,14.90311361729962,14.90311361729962,7.827,1.446,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.10,In-house,Agp3 (R3|N4 hardening),H-SF(Agp)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,7.463630944895598,7.463630944895598,8.127,2.302,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.10 was tested at a 40 nM top dose with an EC50 of 7.46 nM and fold-to-NPS of 0.940. In the 2025-01-06 NPS IP1 assay (plate AXN251223P3), NPSv9.10 was tested at a 5000 nM top dose with an EC50 of 165.22 nM and fold-to-NPS of 56.31. A 2026-01-06 note says NPSv9.10 was roughly as potent as NPSv1."
NPSv9.10,In-house,Agp3 (R3|N4 hardening),H-SF(Agp)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,34.55180767472668,12.51447174710856,7.462,2.227,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.10 was tested at a 40 nM top dose with an EC50 of 7.46 nM and fold-to-NPS of 0.940. In the 2025-01-06 NPS IP1 assay (plate AXN251223P3), NPSv9.10 was tested at a 5000 nM top dose with an EC50 of 165.22 nM and fold-to-NPS of 56.31. A 2026-01-06 note says NPSv9.10 was roughly as potent as NPSv1."
NPSv9.10,In-house,Agp3 (R3|N4 hardening),H-SF(Agp)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,165.2159768304863,,6.782,1.996,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.10 was tested at a 40 nM top dose with an EC50 of 7.46 nM and fold-to-NPS of 0.940. In the 2025-01-06 NPS IP1 assay (plate AXN251223P3), NPSv9.10 was tested at a 5000 nM top dose with an EC50 of 165.22 nM and fold-to-NPS of 56.31. A 2026-01-06 note says NPSv9.10 was roughly as potent as NPSv1."
NPSv9.10,In-house,Agp3 (R3|N4 hardening),H-SF(Agp)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,4770.085785435835,93.34536088518473,5.321,0.92,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.10 was tested at a 40 nM top dose with an EC50 of 7.46 nM and fold-to-NPS of 0.940. In the 2025-01-06 NPS IP1 assay (plate AXN251223P3), NPSv9.10 was tested at a 5000 nM top dose with an EC50 of 165.22 nM and fold-to-NPS of 56.31. A 2026-01-06 note says NPSv9.10 was roughly as potent as NPSv1."
NPSv9.10,In-house,Agp3 (R3|N4 hardening),H-SF(Agp)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,3887.777248128599,17.64777816900923,5.41,0.984,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.10 was tested at a 40 nM top dose with an EC50 of 7.46 nM and fold-to-NPS of 0.940. In the 2025-01-06 NPS IP1 assay (plate AXN251223P3), NPSv9.10 was tested at a 5000 nM top dose with an EC50 of 165.22 nM and fold-to-NPS of 56.31. A 2026-01-06 note says NPSv9.10 was roughly as potent as NPSv1."
NPSv9.10 ChinaPeptides,In-house,,H-SF(Agp)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,236.9806064994074,236.9806064994074,6.625,5.954,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.11,In-house,"Lys3 (R3→K, R3|N4 hardening)",H-SFKNGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,7.598007417278511,7.598007417278511,8.119,2.472,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.11 was tested at a top dose of 40 nM with an EC50 of 7.60 nM and a fold-to-NPS of 1.191."
NPSv9.11,In-house,"Lys3 (R3→K, R3|N4 hardening)",H-SFKNGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.175032551539204,1.043329951234296,8.663,1.118,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.11 was tested at a top dose of 40 nM with an EC50 of 7.60 nM and a fold-to-NPS of 1.191."
NPSv9.11,In-house,"Lys3 (R3→K, R3|N4 hardening)",H-SFKNGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,58.73209068650525,1.043329951234296,7.231,1.444,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.11 was tested at a top dose of 40 nM with an EC50 of 7.60 nM and a fold-to-NPS of 1.191."
NPSv9.11,In-house,"Lys3 (R3→K, R3|N4 hardening)",H-SFKNGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,219.2292803712844,,6.659,1.041,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.11 was tested at a top dose of 40 nM with an EC50 of 7.60 nM and a fold-to-NPS of 1.191."
NPSv9.11,In-house,"Lys3 (R3→K, R3|N4 hardening)",H-SFKNGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,54.99001538879062,1.199026117236351,7.26,0.992,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.11 was tested at a top dose of 40 nM with an EC50 of 7.60 nM and a fold-to-NPS of 1.191."
NPSv9.11,In-house,"Lys3 (R3→K, R3|N4 hardening)",H-SFKNGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,1086.41077164728,1.199026117236351,5.964,6.48,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.11 was tested at a top dose of 40 nM with an EC50 of 7.60 nM and a fold-to-NPS of 1.191."
NPSv9.11,In-house,"Lys3 (R3→K, R3|N4 hardening)",H-SFKNGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,226.1869169584779,0.7366814938712005,6.646,0.818,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.11 was tested at a top dose of 40 nM with an EC50 of 7.60 nM and a fold-to-NPS of 1.191."
NPSv9.11,In-house,"Lys3 (R3→K, R3|N4 hardening)",H-SFKNGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,0.7366814938712005,,5.984,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.11 was tested at a top dose of 40 nM with an EC50 of 7.60 nM and a fold-to-NPS of 1.191."
NPSv9.11 ChinaPeptides,In-house,,H-SFKNGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,134.0276502681951,134.0276502681951,6.873,2.08,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.12,In-house,Dap3 (R3|N4 hardening),H-SF(Dap)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,7.703575616361252,7.398,-0.078,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR dataset, NPSv9.12 appears twice with top dose 40 nM, EC50 40.00 nM, and fold-to-NPS values 7.704 and 6.268. In the 20250106 NPS IP1 dataset, NPSv9.12 shows EC50 5000.00 nM (plate AXN251223P1, top dose 5000 nM, fold to NPS 1704.49) and EC50 3444.26 nM (plate AXN251223P2, top dose 5000 nM, fold to NPS 1450.56)."
NPSv9.12,In-house,Dap3 (R3|N4 hardening),H-SF(Dap)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,7.703575616361252,7.398,5.615,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR dataset, NPSv9.12 appears twice with top dose 40 nM, EC50 40.00 nM, and fold-to-NPS values 7.704 and 6.268. In the 20250106 NPS IP1 dataset, NPSv9.12 shows EC50 5000.00 nM (plate AXN251223P1, top dose 5000 nM, fold to NPS 1704.49) and EC50 3444.26 nM (plate AXN251223P2, top dose 5000 nM, fold to NPS 1450.56)."
NPSv9.12,In-house,Dap3 (R3|N4 hardening),H-SF(Dap)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,280.066099151951,108.0863756244188,6.553,5.659,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR dataset, NPSv9.12 appears twice with top dose 40 nM, EC50 40.00 nM, and fold-to-NPS values 7.704 and 6.268. In the 20250106 NPS IP1 dataset, NPSv9.12 shows EC50 5000.00 nM (plate AXN251223P1, top dose 5000 nM, fold to NPS 1704.49) and EC50 3444.26 nM (plate AXN251223P2, top dose 5000 nM, fold to NPS 1450.56)."
NPSv9.12,In-house,Dap3 (R3|N4 hardening),H-SF(Dap)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,3444.255005967013,,5.463,0.814,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR dataset, NPSv9.12 appears twice with top dose 40 nM, EC50 40.00 nM, and fold-to-NPS values 7.704 and 6.268. In the 20250106 NPS IP1 dataset, NPSv9.12 shows EC50 5000.00 nM (plate AXN251223P1, top dose 5000 nM, fold to NPS 1704.49) and EC50 3444.26 nM (plate AXN251223P2, top dose 5000 nM, fold to NPS 1450.56)."
NPSv9.12,In-house,Dap3 (R3|N4 hardening),H-SF(Dap)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,89.30265170652972,,-0.364,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR dataset, NPSv9.12 appears twice with top dose 40 nM, EC50 40.00 nM, and fold-to-NPS values 7.704 and 6.268. In the 20250106 NPS IP1 dataset, NPSv9.12 shows EC50 5000.00 nM (plate AXN251223P1, top dose 5000 nM, fold to NPS 1704.49) and EC50 3444.26 nM (plate AXN251223P2, top dose 5000 nM, fold to NPS 1450.56)."
NPSv9.12,In-house,Dap3 (R3|N4 hardening),H-SF(Dap)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,19.03052922335446,,0.523,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR dataset, NPSv9.12 appears twice with top dose 40 nM, EC50 40.00 nM, and fold-to-NPS values 7.704 and 6.268. In the 20250106 NPS IP1 dataset, NPSv9.12 shows EC50 5000.00 nM (plate AXN251223P1, top dose 5000 nM, fold to NPS 1704.49) and EC50 3444.26 nM (plate AXN251223P2, top dose 5000 nM, fold to NPS 1450.56)."
NPSv9.12 ChinaPeptides,In-house,,H-SF(Dap)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,878.2945152060238,878.2945152060238,6.056,1.561,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.12 Noah,In-house,,H-SF(Dap)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,,1000,,1,"Z'=0.505; 0.619; 0.668; plate_instance=1
lab notes: On 2025-01-06 NPS FLIPR, NPSv9.12 was run at a 40 nM top dose with EC50 40.00 nM and fold-to-NPS values of 7.704 and 6.268 across two entries. On 2025-01-06 NPS IP1, NPSv9.12 was run at a 5000 nM top dose with EC50 values of 5000.00 nM (fold 1704.49) and 3444.26 nM (fold 1450.56) across two entries."
NPSv9.13,In-house,"His4 (N4→H, R3|N4 hardening)",H-SFRHGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,40,7.398,60.256,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.13 was tested at a 40 nM top dose with an EC50 of 40.00 nM and a 6.268 fold to NPS."
NPSv9.13,In-house,"His4 (N4→H, R3|N4 hardening)",H-SFRHGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,385.9316638168909,,-12.455,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.13 was tested at a 40 nM top dose with an EC50 of 40.00 nM and a 6.268 fold to NPS."
NPSv9.13,In-house,"His4 (N4→H, R3|N4 hardening)",H-SFRHGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,89.30265170652972,,35.259,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.13 was tested at a 40 nM top dose with an EC50 of 40.00 nM and a 6.268 fold to NPS."
NPSv9.13,In-house,"His4 (N4→H, R3|N4 hardening)",H-SFRHGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,19.03052922335446,,85.039,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv9.13 was tested at a 40 nM top dose with an EC50 of 40.00 nM and a 6.268 fold to NPS."
NPSv9.13 ChinaPeptides,In-house,,H-SFRHGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,116.2447323865594,116.2447323865594,6.935,2.198,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,,291,,,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,40,7.398,7.55,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,479.6847525320777,,2.521,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,479.6847525320777,,0.375,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,858.4837128688422,479.6847525320777,6.066,1.775,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,1168.32,312.325,5.932,,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,1176.391023813633,,5.929,3.631,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,109.0221660022272,,-30.222,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,109.0221660022272,,0.063,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,109.0221660022272,,-0.269,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,-32.287,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,-0.195,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14,In-house,"Gln4 (N4→Q, R3|N4 hardening)",H-SFRQGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,36716.928,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv9.14 had a top dose of 40 nM, an EC50 of 40.00 nM, and a fold to NPS of 6.268. In the 2025-01-06 NPS IP1 assay (plate AXN251223P2), NPSv9.14 had a top dose of 5000 nM, an EC50 of 1176,39 nM, and folds to NPS of 495,44."
NPSv9.14 ChinaPeptides,In-house,,H-SFRQGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,5.24119563830211,5.24119563830211,8.281,0.402,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.15,In-house,β-homo-Arg3 (R3|N4 hardening),H-SF(β-homo-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,6.379397995401206,1.736363116804855,8.195,1.376,"plates=3-4; Z'=0.539
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.15 was tested at a 1000 nM top dose with EC50 6.38 nM (fold to NPS 1.736), and notes summarize this as a ~1.7x potency loss. In the 20251212 IP1 assay, NPSv9.15 was tested at a 5000 nM top dose with EC50 25.49 nM (fold to NPS 14.66), noted as ~15x potency loss; there is also a 20260106 note questioning whether it is 2x more potent than NPSv1."
NPSv9.15,In-house,β-homo-Arg3 (R3|N4 hardening),H-SF(β-homo-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.669202189498451,2.669202189498451,8.574,1.667,"plates=3-4; Z'=0.539
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.15 was tested at a 1000 nM top dose with EC50 6.38 nM (fold to NPS 1.736), and notes summarize this as a ~1.7x potency loss. In the 20251212 IP1 assay, NPSv9.15 was tested at a 5000 nM top dose with EC50 25.49 nM (fold to NPS 14.66), noted as ~15x potency loss; there is also a 20260106 note questioning whether it is 2x more potent than NPSv1."
NPSv9.15,In-house,β-homo-Arg3 (R3|N4 hardening),H-SF(β-homo-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,12.8258754110307,6.15237687254752,7.892,1.426,"plates=3-4; Z'=0.539
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.15 was tested at a 1000 nM top dose with EC50 6.38 nM (fold to NPS 1.736), and notes summarize this as a ~1.7x potency loss. In the 20251212 IP1 assay, NPSv9.15 was tested at a 5000 nM top dose with EC50 25.49 nM (fold to NPS 14.66), noted as ~15x potency loss; there is also a 20260106 note questioning whether it is 2x more potent than NPSv1."
NPSv9.15,In-house,β-homo-Arg3 (R3|N4 hardening),H-SF(β-homo-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,5.509799404130447,6.15237687254752,8.259,1.324,"plates=3-4; Z'=0.539
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.15 was tested at a 1000 nM top dose with EC50 6.38 nM (fold to NPS 1.736), and notes summarize this as a ~1.7x potency loss. In the 20251212 IP1 assay, NPSv9.15 was tested at a 5000 nM top dose with EC50 25.49 nM (fold to NPS 14.66), noted as ~15x potency loss; there is also a 20260106 note questioning whether it is 2x more potent than NPSv1."
NPSv9.15,In-house,β-homo-Arg3 (R3|N4 hardening),H-SF(β-homo-Arg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,25.49447323033007,14.66158064130058,7.594,0.912,"plates=3-4; Z'=0.539
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.15 was tested at a 1000 nM top dose with EC50 6.38 nM (fold to NPS 1.736), and notes summarize this as a ~1.7x potency loss. In the 20251212 IP1 assay, NPSv9.15 was tested at a 5000 nM top dose with EC50 25.49 nM (fold to NPS 14.66), noted as ~15x potency loss; there is also a 20260106 note questioning whether it is 2x more potent than NPSv1."
NPSv9.15,In-house,β-homo-Arg3 (R3|N4 hardening),H-SF(β-homo-Arg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,6.190254026419729,,8.208,0.939,"plates=3-4; Z'=0.539
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.15 was tested at a 1000 nM top dose with EC50 6.38 nM (fold to NPS 1.736), and notes summarize this as a ~1.7x potency loss. In the 20251212 IP1 assay, NPSv9.15 was tested at a 5000 nM top dose with EC50 25.49 nM (fold to NPS 14.66), noted as ~15x potency loss; there is also a 20260106 note questioning whether it is 2x more potent than NPSv1."
NPSv9.15,In-house,β-homo-Arg3 (R3|N4 hardening),H-SF(β-homo-Arg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,731.2076689762926,15.94356877384699,6.136,1.096,"plates=3-4; Z'=0.539
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.15 was tested at a 1000 nM top dose with EC50 6.38 nM (fold to NPS 1.736), and notes summarize this as a ~1.7x potency loss. In the 20251212 IP1 assay, NPSv9.15 was tested at a 5000 nM top dose with EC50 25.49 nM (fold to NPS 14.66), noted as ~15x potency loss; there is also a 20260106 note questioning whether it is 2x more potent than NPSv1."
NPSv9.15,In-house,β-homo-Arg3 (R3|N4 hardening),H-SF(β-homo-Arg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,340.2154982417985,15.94356877384699,6.468,1.861,"plates=3-4; Z'=0.539
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.15 was tested at a 1000 nM top dose with EC50 6.38 nM (fold to NPS 1.736), and notes summarize this as a ~1.7x potency loss. In the 20251212 IP1 assay, NPSv9.15 was tested at a 5000 nM top dose with EC50 25.49 nM (fold to NPS 14.66), noted as ~15x potency loss; there is also a 20260106 note questioning whether it is 2x more potent than NPSv1."
NPSv9.15,In-house,β-homo-Arg3 (R3|N4 hardening),H-SF(β-homo-Arg)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,1487.477893692768,4.844654375067749,5.828,1.14,"plates=3-4; Z'=0.539
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.15 was tested at a 1000 nM top dose with EC50 6.38 nM (fold to NPS 1.736), and notes summarize this as a ~1.7x potency loss. In the 20251212 IP1 assay, NPSv9.15 was tested at a 5000 nM top dose with EC50 25.49 nM (fold to NPS 14.66), noted as ~15x potency loss; there is also a 20260106 note questioning whether it is 2x more potent than NPSv1."
NPSv9.15,In-house,β-homo-Arg3 (R3|N4 hardening),H-SF(β-homo-Arg)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,1005.782511358245,4.844654375067749,5.997,1.461,"plates=3-4; Z'=0.539
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.15 was tested at a 1000 nM top dose with EC50 6.38 nM (fold to NPS 1.736), and notes summarize this as a ~1.7x potency loss. In the 20251212 IP1 assay, NPSv9.15 was tested at a 5000 nM top dose with EC50 25.49 nM (fold to NPS 14.66), noted as ~15x potency loss; there is also a 20260106 note questioning whether it is 2x more potent than NPSv1."
NPSv9.15 ChinaPeptides,In-house,,H-SF(β-homo-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,4.604609995514778,4.604609995514778,8.337,1.769,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.16,In-house,β-homo-Asn4 (R3|N4 hardening),H-SFR(β-homo-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.03168192142858,2.03168192142858,8.692,2.626,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR assay, NPSv9.16 was tested at a 40 nM top dose with an EC50 of 2.03 nM and a 0.318 fold-to-NPS. A 20260106 note says NPSv9.16 was ~3x more potent than NPSv1 (questioned), and it “performed best in v9 in vivo studies.”"
NPSv9.16,In-house,β-homo-Asn4 (R3|N4 hardening),H-SFR(β-homo-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,7.870308052442373,3.03740108143056,8.104,1.422,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR assay, NPSv9.16 was tested at a 40 nM top dose with an EC50 of 2.03 nM and a 0.318 fold-to-NPS. A 20260106 note says NPSv9.16 was ~3x more potent than NPSv1 (questioned), and it “performed best in v9 in vivo studies.”"
NPSv9.16,In-house,β-homo-Asn4 (R3|N4 hardening),H-SFR(β-homo-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,18.42958554164227,,7.734,0.979,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR assay, NPSv9.16 was tested at a 40 nM top dose with an EC50 of 2.03 nM and a 0.318 fold-to-NPS. A 20260106 note says NPSv9.16 was ~3x more potent than NPSv1 (questioned), and it “performed best in v9 in vivo studies.”"
NPSv9.16,In-house,β-homo-Asn4 (R3|N4 hardening),H-SFR(β-homo-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,517.9069918779527,9.250093542410665,6.286,1.566,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR assay, NPSv9.16 was tested at a 40 nM top dose with an EC50 of 2.03 nM and a 0.318 fold-to-NPS. A 20260106 note says NPSv9.16 was ~3x more potent than NPSv1 (questioned), and it “performed best in v9 in vivo studies.”"
NPSv9.16,In-house,β-homo-Asn4 (R3|N4 hardening),H-SFR(β-homo-Asn)GVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,1470.09024353252,5.595319068102778,5.833,1.393,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR assay, NPSv9.16 was tested at a 40 nM top dose with an EC50 of 2.03 nM and a 0.318 fold-to-NPS. A 20260106 note says NPSv9.16 was ~3x more potent than NPSv1 (questioned), and it “performed best in v9 in vivo studies.”"
NPSv9.16 ChinaPeptides,In-house,,H-SFR(β-homo-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,,1000,,-8.903,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.17,In-house,β-homo-Gln4 (R3|N4 hardening),H-SFR(β-homo-Gln)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,40,7.398,66.455,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.17 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS of 6.268. The NPSv9.17 entry also notes “Dead?”"
NPSv9.17,In-house,β-homo-Gln4 (R3|N4 hardening),H-SFR(β-homo-Gln)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,385.9316638168909,,-0.075,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.17 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS of 6.268. The NPSv9.17 entry also notes “Dead?”"
NPSv9.17,In-house,β-homo-Gln4 (R3|N4 hardening),H-SFR(β-homo-Gln)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,89.30265170652972,,-1.409,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.17 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS of 6.268. The NPSv9.17 entry also notes “Dead?”"
NPSv9.17,In-house,β-homo-Gln4 (R3|N4 hardening),H-SFR(β-homo-Gln)GVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,19.03052922335446,,70.852,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.17 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS of 6.268. The NPSv9.17 entry also notes “Dead?”"
NPSv9.17 ChinaPeptides,In-house,,H-SFR(β-homo-Gln)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,144.9236939424689,144.9236939424689,6.839,4.435,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.18,In-house,α-Me-L-Arg3 (R3|N4 hardening),H-SF(⍺-methyl-L-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,114.8912155035984,31.27142548389947,6.94,1.467,"plates=1-2; Z'=0.526
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.18 was tested at a 1000 nM top dose with an EC50 of 114.89 nM and a 31.271-fold vs NPS. In the 20251212 IP1 assay, NPSv9.18 was tested at a 5000 nM top dose with EC50 >5000 nM (fold N/A). The NPSv9.18 section notes ""20251212 Results: Dead agonist."""
NPSv9.18,In-house,α-Me-L-Arg3 (R3|N4 hardening),H-SF(⍺-methyl-L-Arg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,479.6847525320777,,2.819,"plates=1-2; Z'=0.526
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.18 was tested at a 1000 nM top dose with an EC50 of 114.89 nM and a 31.271-fold vs NPS. In the 20251212 IP1 assay, NPSv9.18 was tested at a 5000 nM top dose with EC50 >5000 nM (fold N/A). The NPSv9.18 section notes ""20251212 Results: Dead agonist."""
NPSv9.18,In-house,α-Me-L-Arg3 (R3|N4 hardening),H-SF(⍺-methyl-L-Arg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,1000,21.80443320044543,6,-1.993,"plates=1-2; Z'=0.526
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.18 was tested at a 1000 nM top dose with an EC50 of 114.89 nM and a 31.271-fold vs NPS. In the 20251212 IP1 assay, NPSv9.18 was tested at a 5000 nM top dose with EC50 >5000 nM (fold N/A). The NPSv9.18 section notes ""20251212 Results: Dead agonist."""
NPSv9.18,In-house,α-Me-L-Arg3 (R3|N4 hardening),H-SF(⍺-methyl-L-Arg)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,-11.922,"plates=1-2; Z'=0.526
lab notes: In the 20251212 FLIPR Ca2+ NPS assay, NPSv9.18 was tested at a 1000 nM top dose with an EC50 of 114.89 nM and a 31.271-fold vs NPS. In the 20251212 IP1 assay, NPSv9.18 was tested at a 5000 nM top dose with EC50 >5000 nM (fold N/A). The NPSv9.18 section notes ""20251212 Results: Dead agonist."""
NPSv9.19,In-house,α-Me-L-Asn4 (R3|N4 hardening),H-SFR(⍺-methyl-L-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,37.53459336723901,37.53459336723901,7.426,2.587,"plates=3-4; Z'=0.539
lab notes: 20251212 FLIPR Ca2+ NPS experiment includes NPSv9.19 with top dose 1000 nM and EC50 >1000 nM (fold to NPS listed as N/A). 20251212 IP1 experiment includes NPSv9.19 with top dose 5000 nM and EC50 >5000 nM (fold to NPS listed as N/A)."
NPSv9.19,In-house,α-Me-L-Asn4 (R3|N4 hardening),H-SFR(⍺-methyl-L-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,479.6847525320777,,6.251,"plates=3-4; Z'=0.539
lab notes: 20251212 FLIPR Ca2+ NPS experiment includes NPSv9.19 with top dose 1000 nM and EC50 >1000 nM (fold to NPS listed as N/A). 20251212 IP1 experiment includes NPSv9.19 with top dose 5000 nM and EC50 >5000 nM (fold to NPS listed as N/A)."
NPSv9.19,In-house,α-Me-L-Asn4 (R3|N4 hardening),H-SFR(⍺-methyl-L-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,205.4070474300589,479.6847525320777,6.687,3.49,"plates=3-4; Z'=0.539
lab notes: 20251212 FLIPR Ca2+ NPS experiment includes NPSv9.19 with top dose 1000 nM and EC50 >1000 nM (fold to NPS listed as N/A). 20251212 IP1 experiment includes NPSv9.19 with top dose 5000 nM and EC50 >5000 nM (fold to NPS listed as N/A)."
NPSv9.19,In-house,α-Me-L-Asn4 (R3|N4 hardening),H-SFR(⍺-methyl-L-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,1751.507754030587,,5.757,1.363,"plates=3-4; Z'=0.539
lab notes: 20251212 FLIPR Ca2+ NPS experiment includes NPSv9.19 with top dose 1000 nM and EC50 >1000 nM (fold to NPS listed as N/A). 20251212 IP1 experiment includes NPSv9.19 with top dose 5000 nM and EC50 >5000 nM (fold to NPS listed as N/A)."
NPSv9.19,In-house,α-Me-L-Asn4 (R3|N4 hardening),H-SFR(⍺-methyl-L-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,1000,21.80443320044543,6,6.736,"plates=3-4; Z'=0.539
lab notes: 20251212 FLIPR Ca2+ NPS experiment includes NPSv9.19 with top dose 1000 nM and EC50 >1000 nM (fold to NPS listed as N/A). 20251212 IP1 experiment includes NPSv9.19 with top dose 5000 nM and EC50 >5000 nM (fold to NPS listed as N/A)."
NPSv9.19,In-house,α-Me-L-Asn4 (R3|N4 hardening),H-SFR(⍺-methyl-L-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,21.80443320044543,,0.798,"plates=3-4; Z'=0.539
lab notes: 20251212 FLIPR Ca2+ NPS experiment includes NPSv9.19 with top dose 1000 nM and EC50 >1000 nM (fold to NPS listed as N/A). 20251212 IP1 experiment includes NPSv9.19 with top dose 5000 nM and EC50 >5000 nM (fold to NPS listed as N/A)."
NPSv9.19,In-house,α-Me-L-Asn4 (R3|N4 hardening),H-SFR(⍺-methyl-L-Asn)GVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,8.109,"plates=3-4; Z'=0.539
lab notes: 20251212 FLIPR Ca2+ NPS experiment includes NPSv9.19 with top dose 1000 nM and EC50 >1000 nM (fold to NPS listed as N/A). 20251212 IP1 experiment includes NPSv9.19 with top dose 5000 nM and EC50 >5000 nM (fold to NPS listed as N/A)."
NPSv9.19,In-house,α-Me-L-Asn4 (R3|N4 hardening),H-SFR(⍺-methyl-L-Asn)GVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,16.28479453580501,,0.549,"plates=3-4; Z'=0.539
lab notes: 20251212 FLIPR Ca2+ NPS experiment includes NPSv9.19 with top dose 1000 nM and EC50 >1000 nM (fold to NPS listed as N/A). 20251212 IP1 experiment includes NPSv9.19 with top dose 5000 nM and EC50 >5000 nM (fold to NPS listed as N/A)."
NPSv9.19 ChinaPeptides,In-house,,H-SFR(⍺-methyl-L-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,21.14035073699754,21.14035073699754,7.675,1.008,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.20,In-house,N-Me-Arg3 + N-Me-Asn4 (R3|N4 hardening),H-SF(N-Me-Arg)(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,40,7.398,-182.994,"plates=3-4; Z'=0.539
lab notes: On January 6, 2025 in the NPS FLIPR assay, NPSv9.20 (top dose 40 nM) showed EC50 40.00 nM with a 5.037-fold vs NPS. On January 6, 2025 in the NPS IP1 assay (plate AXN251223P3), NPSv9.20 (top dose 5000 nM) showed EC50 1752.67 nM with a 597.32-fold vs NPS."
NPSv9.20,In-house,N-Me-Arg3 + N-Me-Asn4 (R3|N4 hardening),H-SF(N-Me-Arg)(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,215.2893744944427,77.9766089209308,6.667,7.957,"plates=3-4; Z'=0.539
lab notes: On January 6, 2025 in the NPS FLIPR assay, NPSv9.20 (top dose 40 nM) showed EC50 40.00 nM with a 5.037-fold vs NPS. On January 6, 2025 in the NPS IP1 assay (plate AXN251223P3), NPSv9.20 (top dose 5000 nM) showed EC50 1752.67 nM with a 597.32-fold vs NPS."
NPSv9.20,In-house,N-Me-Arg3 + N-Me-Asn4 (R3|N4 hardening),H-SF(N-Me-Arg)(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,1752.669322334924,,5.756,2.111,"plates=3-4; Z'=0.539
lab notes: On January 6, 2025 in the NPS FLIPR assay, NPSv9.20 (top dose 40 nM) showed EC50 40.00 nM with a 5.037-fold vs NPS. On January 6, 2025 in the NPS IP1 assay (plate AXN251223P3), NPSv9.20 (top dose 5000 nM) showed EC50 1752.67 nM with a 597.32-fold vs NPS."
NPSv9.20,In-house,N-Me-Arg3 + N-Me-Asn4 (R3|N4 hardening),H-SF(N-Me-Arg)(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,97.84453056398851,,3.097,"plates=3-4; Z'=0.539
lab notes: On January 6, 2025 in the NPS FLIPR assay, NPSv9.20 (top dose 40 nM) showed EC50 40.00 nM with a 5.037-fold vs NPS. On January 6, 2025 in the NPS IP1 assay (plate AXN251223P3), NPSv9.20 (top dose 5000 nM) showed EC50 1752.67 nM with a 597.32-fold vs NPS."
NPSv9.20,In-house,N-Me-Arg3 + N-Me-Asn4 (R3|N4 hardening),H-SF(N-Me-Arg)(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,22.69648830511582,,13.131,"plates=3-4; Z'=0.539
lab notes: On January 6, 2025 in the NPS FLIPR assay, NPSv9.20 (top dose 40 nM) showed EC50 40.00 nM with a 5.037-fold vs NPS. On January 6, 2025 in the NPS IP1 assay (plate AXN251223P3), NPSv9.20 (top dose 5000 nM) showed EC50 1752.67 nM with a 597.32-fold vs NPS."
NPSv9.20 ChinaPeptides,In-house,,H-SF(N-Me-Arg)(N-Me-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,3.518745792393482,3.518745792393482,8.454,1.435,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.21,In-house,D-Arg3 + D-Asn4 (R3|N4 hardening),H-SF(D-Arg)(D-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,7.703575616361252,7.398,6.583,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 (NPS FLIPR), NPSv9.21 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS of 7.704."
NPSv9.21,In-house,D-Arg3 + D-Asn4 (R3|N4 hardening),H-SF(D-Arg)(D-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,7.703575616361252,7.398,9.567,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 (NPS FLIPR), NPSv9.21 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS of 7.704."
NPSv9.21,In-house,D-Arg3 + D-Asn4 (R3|N4 hardening),H-SF(D-Arg)(D-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,362.1944143970915,,-0.058,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 (NPS FLIPR), NPSv9.21 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS of 7.704."
NPSv9.21,In-house,D-Arg3 + D-Asn4 (R3|N4 hardening),H-SF(D-Arg)(D-Asn)GVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,97.84453056398851,,-5.494,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 (NPS FLIPR), NPSv9.21 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS of 7.704."
NPSv9.21,In-house,D-Arg3 + D-Asn4 (R3|N4 hardening),H-SF(D-Arg)(D-Asn)GVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,22.69648830511582,,18.221,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 (NPS FLIPR), NPSv9.21 was tested at a top dose of 40 nM with an EC50 of 40.00 nM and a fold-to-NPS of 7.704."
NPSv9.21 ChinaPeptides,In-house,,H-SF(D-Arg)(D-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,40,7.398,2.438,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.21 Noah,In-house,,H-SF(D-Arg)(D-Asn)GVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,,1000,,3.22,"Z'=0.505; 0.619; 0.668; plate_instance=1
lab notes: The 2025-01-06 NPS FLIPR experiment lists NPSv9.21 tested at 40 nM top dose with an EC50 of 40.00 nM, reported with fold‑to‑NPS values of 7.704 and 5.037 in separate blocks. The 2025-01-06 NPS IP1 experiment includes NPSv9.21 on plates AXN251223P1 and AXN251223P3 at 5000 nM top dose with EC50 5000.00 nM and fold‑to‑NPS values 1704.49 and 1704.04."
NPSv9.22,In-house,Nω-Me-Arg3 + Gln4 (R3|N4 hardening),H-SF(Arg(NωMe))QGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,40,7.398,0.607,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.22 was tested at a 40 nM top dose with an EC50 of 40.00 nM and a fold to NPS of 6.268. On 2025-01-06 in the NPS IP1 assay (plate AXN251223P2), NPSv9.22 was tested at a 5000 nM top dose with an EC50 of 5000.00 nM and a fold to NPS of 2105.76."
NPSv9.22,In-house,Nω-Me-Arg3 + Gln4 (R3|N4 hardening),H-SF(Arg(NωMe))QGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,385.9316638168909,,2.534,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.22 was tested at a 40 nM top dose with an EC50 of 40.00 nM and a fold to NPS of 6.268. On 2025-01-06 in the NPS IP1 assay (plate AXN251223P2), NPSv9.22 was tested at a 5000 nM top dose with an EC50 of 5000.00 nM and a fold to NPS of 2105.76."
NPSv9.22,In-house,Nω-Me-Arg3 + Gln4 (R3|N4 hardening),H-SF(Arg(NωMe))QGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,89.30265170652972,,-6.588,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.22 was tested at a 40 nM top dose with an EC50 of 40.00 nM and a fold to NPS of 6.268. On 2025-01-06 in the NPS IP1 assay (plate AXN251223P2), NPSv9.22 was tested at a 5000 nM top dose with an EC50 of 5000.00 nM and a fold to NPS of 2105.76."
NPSv9.22,In-house,Nω-Me-Arg3 + Gln4 (R3|N4 hardening),H-SF(Arg(NωMe))QGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,19.03052922335446,,1.21,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv9.22 was tested at a 40 nM top dose with an EC50 of 40.00 nM and a fold to NPS of 6.268. On 2025-01-06 in the NPS IP1 assay (plate AXN251223P2), NPSv9.22 was tested at a 5000 nM top dose with an EC50 of 5000.00 nM and a fold to NPS of 2105.76."
NPSv9.22 ChinaPeptides,In-house,,H-SF(Arg(NωMe))QGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,,1000,,-7.91,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.23,In-house,Agb3 (R3|N4 hardening),H-SF(Agb)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,8.660539696122203,3.717236131578316,8.062,1.784,20260128 new experiment; receptor=107N
NPSv9.23,In-house,Agb3 (R3|N4 hardening),H-SF(Agb)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,6.924991700125086,1.305186064433337,8.16,6.81,20260128 new experiment; receptor=107I
NPSv9.23,In-house,Agb3 (R3|N4 hardening),H-SF(Agb)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,1634.782685526709,115.8991990266616,5.787,1.579,20260128 new experiment; receptor=107N
NPSv9.23,In-house,Agb3 (R3|N4 hardening),H-SF(Agb)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,1571.262484548871,7.674436856694813,5.804,1.144,plates=5; Z'=0.603
NPSv9.30,In-house,Nε-trimethyl-Lys3 (R3|N4 hardening),H-SF(Trimethyl N𝜀 lysine)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,7.703575616361252,7.398,0.062,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv9.30 was tested at 40 nM top dose with EC50 40.00 nM and fold-to-NPS values reported as 7.704 and 5.037. On 2025-01-06 NPS IP1, NPSv9.30 was tested at 5000 nM top dose with EC50 5000.00 nM and folds to NPS 1704.49 (AXN251223P1) and 1704.04 (AXN251223P3)."
NPSv9.30,In-house,Nε-trimethyl-Lys3 (R3|N4 hardening),H-SF(Trimethyl N𝜀 lysine)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,7.703575616361252,7.398,28.021,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv9.30 was tested at 40 nM top dose with EC50 40.00 nM and fold-to-NPS values reported as 7.704 and 5.037. On 2025-01-06 NPS IP1, NPSv9.30 was tested at 5000 nM top dose with EC50 5000.00 nM and folds to NPS 1704.49 (AXN251223P1) and 1704.04 (AXN251223P3)."
NPSv9.30,In-house,Nε-trimethyl-Lys3 (R3|N4 hardening),H-SF(Trimethyl N𝜀 lysine)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,385.9316638168909,,-5.926,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv9.30 was tested at 40 nM top dose with EC50 40.00 nM and fold-to-NPS values reported as 7.704 and 5.037. On 2025-01-06 NPS IP1, NPSv9.30 was tested at 5000 nM top dose with EC50 5000.00 nM and folds to NPS 1704.49 (AXN251223P1) and 1704.04 (AXN251223P3)."
NPSv9.30,In-house,Nε-trimethyl-Lys3 (R3|N4 hardening),H-SF(Trimethyl N𝜀 lysine)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,89.30265170652972,,-6.149,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv9.30 was tested at 40 nM top dose with EC50 40.00 nM and fold-to-NPS values reported as 7.704 and 5.037. On 2025-01-06 NPS IP1, NPSv9.30 was tested at 5000 nM top dose with EC50 5000.00 nM and folds to NPS 1704.49 (AXN251223P1) and 1704.04 (AXN251223P3)."
NPSv9.30,In-house,Nε-trimethyl-Lys3 (R3|N4 hardening),H-SF(Trimethyl N𝜀 lysine)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,19.03052922335446,,-28.994,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv9.30 was tested at 40 nM top dose with EC50 40.00 nM and fold-to-NPS values reported as 7.704 and 5.037. On 2025-01-06 NPS IP1, NPSv9.30 was tested at 5000 nM top dose with EC50 5000.00 nM and folds to NPS 1704.49 (AXN251223P1) and 1704.04 (AXN251223P3)."
NPSv9.30  ChinaPeptides,In-house,,H-SF(Trimethyl N𝜀 lysine)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,40,7.398,2.045,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.30 Noah,In-house,,H-SF(Trimethyl N𝜀 lysine)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,360.308376621128,360.308376621128,6.443,2.266,"Z'=0.505; 0.619; 0.668; plate_instance=1
lab notes: """""
NPSv9.32,In-house,α-Me-Phe2 (R3|N4 hardening),H-S(⍺-Me-Phe)RNGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,6.307855240286017,6.307855240286017,8.2,2.92,"plates=5; Z'=0.603
lab notes: On 2025-01-06 NPS FLIPR, NPSv9.32 had top dose 40 nM, EC50 6.31 nM, and fold to NPS 0.794. On 2025-01-06 NPS IP1, NPSv9.32 had top dose 5000 nM, EC50 86.62 nM, and fold to NPS 29.52. A 2026-01-06 note says “more potent?” but reports ~30x potency loss in IP1."
NPSv9.32,In-house,α-Me-Phe2 (R3|N4 hardening),H-S(⍺-Me-Phe)RNGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,24.05939646458116,8.615929220177959,7.619,1.455,"plates=5; Z'=0.603
lab notes: On 2025-01-06 NPS FLIPR, NPSv9.32 had top dose 40 nM, EC50 6.31 nM, and fold to NPS 0.794. On 2025-01-06 NPS IP1, NPSv9.32 had top dose 5000 nM, EC50 86.62 nM, and fold to NPS 29.52. A 2026-01-06 note says “more potent?” but reports ~30x potency loss in IP1."
NPSv9.32,In-house,α-Me-Phe2 (R3|N4 hardening),H-S(⍺-Me-Phe)RNGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,86.62274451172061,,7.062,0.929,"plates=5; Z'=0.603
lab notes: On 2025-01-06 NPS FLIPR, NPSv9.32 had top dose 40 nM, EC50 6.31 nM, and fold to NPS 0.794. On 2025-01-06 NPS IP1, NPSv9.32 had top dose 5000 nM, EC50 86.62 nM, and fold to NPS 29.52. A 2026-01-06 note says “more potent?” but reports ~30x potency loss in IP1."
NPSv9.32,In-house,α-Me-Phe2 (R3|N4 hardening),H-S(⍺-Me-Phe)RNGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,1330.469810665463,44.37898697772362,5.876,1.714,"plates=5; Z'=0.603
lab notes: On 2025-01-06 NPS FLIPR, NPSv9.32 had top dose 40 nM, EC50 6.31 nM, and fold to NPS 0.794. On 2025-01-06 NPS IP1, NPSv9.32 had top dose 5000 nM, EC50 86.62 nM, and fold to NPS 29.52. A 2026-01-06 note says “more potent?” but reports ~30x potency loss in IP1."
NPSv9.32,In-house,α-Me-Phe2 (R3|N4 hardening),H-S(⍺-Me-Phe)RNGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,1260.407875978365,6.156145617295767,5.899,1.497,"plates=5; Z'=0.603
lab notes: On 2025-01-06 NPS FLIPR, NPSv9.32 had top dose 40 nM, EC50 6.31 nM, and fold to NPS 0.794. On 2025-01-06 NPS IP1, NPSv9.32 had top dose 5000 nM, EC50 86.62 nM, and fold to NPS 29.52. A 2026-01-06 note says “more potent?” but reports ~30x potency loss in IP1."
NPSv9.32 ChinaPeptides,In-house,,H-S(⍺-Me-Phe)RNGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,48.25292990855895,48.25292990855895,7.316,9.392,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.36,In-house,"hArg3 (homoarginine, R3|N4 hardening)",H-SF(hArg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,6.372286956028652,1.73442761340821,8.196,1.515,"plates=3-4; Z'=0.539
lab notes: On 2025-12-12, NPSv9.36 was tested in FLIPR Ca2+ (top dose 1000 nM, EC50 6.37 nM, fold to NPS 1.734) and IP1 (top dose 5000 nM, EC50 54.95 nM, fold to NPS 31.60) assays. Notes also flag a 2026-01-06 observation of ~2x potency loss and in vitro stability as strongest protection against cleavage (11% cleavage at 90 min). In vivo mouse trials report ~20% increased sleep for NPSv9.36 and that this effect was replicated."
NPSv9.36,In-house,"hArg3 (homoarginine, R3|N4 hardening)",H-SF(hArg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,14.59190148454188,14.59190148454188,7.836,1.024,"plates=3-4; Z'=0.539
lab notes: On 2025-12-12, NPSv9.36 was tested in FLIPR Ca2+ (top dose 1000 nM, EC50 6.37 nM, fold to NPS 1.734) and IP1 (top dose 5000 nM, EC50 54.95 nM, fold to NPS 31.60) assays. Notes also flag a 2026-01-06 observation of ~2x potency loss and in vitro stability as strongest protection against cleavage (11% cleavage at 90 min). In vivo mouse trials report ~20% increased sleep for NPSv9.36 and that this effect was replicated."
NPSv9.36,In-house,"hArg3 (homoarginine, R3|N4 hardening)",H-SF(hArg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,8.234632331377552,3.950027572069487,8.084,1.289,"plates=3-4; Z'=0.539
lab notes: On 2025-12-12, NPSv9.36 was tested in FLIPR Ca2+ (top dose 1000 nM, EC50 6.37 nM, fold to NPS 1.734) and IP1 (top dose 5000 nM, EC50 54.95 nM, fold to NPS 31.60) assays. Notes also flag a 2026-01-06 observation of ~2x potency loss and in vitro stability as strongest protection against cleavage (11% cleavage at 90 min). In vivo mouse trials report ~20% increased sleep for NPSv9.36 and that this effect was replicated."
NPSv9.36,In-house,"hArg3 (homoarginine, R3|N4 hardening)",H-SF(hArg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.332922600880095,3.950027572069487,8.632,0.999,"plates=3-4; Z'=0.539
lab notes: On 2025-12-12, NPSv9.36 was tested in FLIPR Ca2+ (top dose 1000 nM, EC50 6.37 nM, fold to NPS 1.734) and IP1 (top dose 5000 nM, EC50 54.95 nM, fold to NPS 31.60) assays. Notes also flag a 2026-01-06 observation of ~2x potency loss and in vitro stability as strongest protection against cleavage (11% cleavage at 90 min). In vivo mouse trials report ~20% increased sleep for NPSv9.36 and that this effect was replicated."
NPSv9.36,In-house,"hArg3 (homoarginine, R3|N4 hardening)",H-SF(hArg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,54.94686303847234,31.59931394333148,7.26,0.813,"plates=3-4; Z'=0.539
lab notes: On 2025-12-12, NPSv9.36 was tested in FLIPR Ca2+ (top dose 1000 nM, EC50 6.37 nM, fold to NPS 1.734) and IP1 (top dose 5000 nM, EC50 54.95 nM, fold to NPS 31.60) assays. Notes also flag a 2026-01-06 observation of ~2x potency loss and in vitro stability as strongest protection against cleavage (11% cleavage at 90 min). In vivo mouse trials report ~20% increased sleep for NPSv9.36 and that this effect was replicated."
NPSv9.36,In-house,"hArg3 (homoarginine, R3|N4 hardening)",H-SF(hArg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,22.04056031266344,,7.657,0.984,"plates=3-4; Z'=0.539
lab notes: On 2025-12-12, NPSv9.36 was tested in FLIPR Ca2+ (top dose 1000 nM, EC50 6.37 nM, fold to NPS 1.734) and IP1 (top dose 5000 nM, EC50 54.95 nM, fold to NPS 31.60) assays. Notes also flag a 2026-01-06 observation of ~2x potency loss and in vitro stability as strongest protection against cleavage (11% cleavage at 90 min). In vivo mouse trials report ~20% increased sleep for NPSv9.36 and that this effect was replicated."
NPSv9.36,In-house,"hArg3 (homoarginine, R3|N4 hardening)",H-SF(hArg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,1055.461566048612,23.0137412125445,5.977,1.003,"plates=3-4; Z'=0.539
lab notes: On 2025-12-12, NPSv9.36 was tested in FLIPR Ca2+ (top dose 1000 nM, EC50 6.37 nM, fold to NPS 1.734) and IP1 (top dose 5000 nM, EC50 54.95 nM, fold to NPS 31.60) assays. Notes also flag a 2026-01-06 observation of ~2x potency loss and in vitro stability as strongest protection against cleavage (11% cleavage at 90 min). In vivo mouse trials report ~20% increased sleep for NPSv9.36 and that this effect was replicated."
NPSv9.36,In-house,"hArg3 (homoarginine, R3|N4 hardening)",H-SF(hArg)NGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,147.3831533676728,23.0137412125445,6.832,1.031,"plates=3-4; Z'=0.539
lab notes: On 2025-12-12, NPSv9.36 was tested in FLIPR Ca2+ (top dose 1000 nM, EC50 6.37 nM, fold to NPS 1.734) and IP1 (top dose 5000 nM, EC50 54.95 nM, fold to NPS 31.60) assays. Notes also flag a 2026-01-06 observation of ~2x potency loss and in vitro stability as strongest protection against cleavage (11% cleavage at 90 min). In vivo mouse trials report ~20% increased sleep for NPSv9.36 and that this effect was replicated."
NPSv9.36,In-house,"hArg3 (homoarginine, R3|N4 hardening)",H-SF(hArg)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,2768.56237279227,9.017093880096583,5.558,1.397,"plates=3-4; Z'=0.539
lab notes: On 2025-12-12, NPSv9.36 was tested in FLIPR Ca2+ (top dose 1000 nM, EC50 6.37 nM, fold to NPS 1.734) and IP1 (top dose 5000 nM, EC50 54.95 nM, fold to NPS 31.60) assays. Notes also flag a 2026-01-06 observation of ~2x potency loss and in vitro stability as strongest protection against cleavage (11% cleavage at 90 min). In vivo mouse trials report ~20% increased sleep for NPSv9.36 and that this effect was replicated."
NPSv9.36,In-house,"hArg3 (homoarginine, R3|N4 hardening)",H-SF(hArg)NGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,675.2131267031449,9.017093880096583,6.171,0.934,"plates=3-4; Z'=0.539
lab notes: On 2025-12-12, NPSv9.36 was tested in FLIPR Ca2+ (top dose 1000 nM, EC50 6.37 nM, fold to NPS 1.734) and IP1 (top dose 5000 nM, EC50 54.95 nM, fold to NPS 31.60) assays. Notes also flag a 2026-01-06 observation of ~2x potency loss and in vitro stability as strongest protection against cleavage (11% cleavage at 90 min). In vivo mouse trials report ~20% increased sleep for NPSv9.36 and that this effect was replicated."
NPSv9.36 ChinaPeptides,In-house,,H-SF(hArg)NGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,422.2130831900972,422.2130831900972,6.374,1.755,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv9.44,In-house,"Pro4 (N4→P, R3|N4 hardening)",H-SFRPGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,40,7.398,11.183,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR experiment, NPSv9.44 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 5.037. In the 20250106 NPS IP1 experiment (plate AXN251223P3), NPSv9.44 was tested at a top dose of 5000 nM with EC50 1924,92 and fold to NPS 656,03."
NPSv9.44,In-house,"Pro4 (N4→P, R3|N4 hardening)",H-SFRPGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,385.9316638168909,,2.034,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR experiment, NPSv9.44 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 5.037. In the 20250106 NPS IP1 experiment (plate AXN251223P3), NPSv9.44 was tested at a top dose of 5000 nM with EC50 1924,92 and fold to NPS 656,03."
NPSv9.44,In-house,"Pro4 (N4→P, R3|N4 hardening)",H-SFRPGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,1924.923793212214,,5.716,1.721,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR experiment, NPSv9.44 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 5.037. In the 20250106 NPS IP1 experiment (plate AXN251223P3), NPSv9.44 was tested at a top dose of 5000 nM with EC50 1924,92 and fold to NPS 656,03."
NPSv9.44,In-house,"Pro4 (N4→P, R3|N4 hardening)",H-SFRPGVGTGMKKTSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,89.30265170652972,,1.798,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR experiment, NPSv9.44 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 5.037. In the 20250106 NPS IP1 experiment (plate AXN251223P3), NPSv9.44 was tested at a top dose of 5000 nM with EC50 1924,92 and fold to NPS 656,03."
NPSv9.44,In-house,"Pro4 (N4→P, R3|N4 hardening)",H-SFRPGVGTGMKKTSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,19.03052922335446,,83.009,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR experiment, NPSv9.44 was tested at a top dose of 40 nM with EC50 40.00 nM and fold to NPS 5.037. In the 20250106 NPS IP1 experiment (plate AXN251223P3), NPSv9.44 was tested at a top dose of 5000 nM with EC50 1924,92 and fold to NPS 656,03."
NPSv9.44 ChinaPeptides,In-house,,H-SFRPGVGTGMKKTSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,,1000,,-85.032,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv10.1,In-house,D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMKK(D-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,3.920304804853708,0.755009112584372,8.407,0.921,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv10.1 was tested at a top dose of 40 nM with an EC50 of 3.92 nM and a fold-to-NPS of 0.755. In the 2025-01-06 NPS IP1 experiment (plate AXN251223P1), NPSv10.1 was tested at a top dose of 5000 nM with an EC50 of 0.45 nM and a fold-to-NPS of 0.16."
NPSv10.1,In-house,D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMKK(D-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.46422680787225,0.5303347712218122,8.834,0.737,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv10.1 was tested at a top dose of 40 nM with an EC50 of 3.92 nM and a fold-to-NPS of 0.755. In the 2025-01-06 NPS IP1 experiment (plate AXN251223P1), NPSv10.1 was tested at a top dose of 5000 nM with an EC50 of 0.45 nM and a fold-to-NPS of 0.16."
NPSv10.1,In-house,D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMKK(D-Thr)SFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.4547376489960107,,9.342,0.902,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv10.1 was tested at a top dose of 40 nM with an EC50 of 3.92 nM and a fold-to-NPS of 0.755. In the 2025-01-06 NPS IP1 experiment (plate AXN251223P1), NPSv10.1 was tested at a top dose of 5000 nM with an EC50 of 0.45 nM and a fold-to-NPS of 0.16."
NPSv10.1,In-house,D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMKK(D-Thr)SFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,12.80663941558315,0.250611924344001,7.893,0.803,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv10.1 was tested at a top dose of 40 nM with an EC50 of 3.92 nM and a fold-to-NPS of 0.755. In the 2025-01-06 NPS IP1 experiment (plate AXN251223P1), NPSv10.1 was tested at a top dose of 5000 nM with an EC50 of 0.45 nM and a fold-to-NPS of 0.16."
NPSv10.1,In-house,D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMKK(D-Thr)SFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,58.62501641158844,0.266116399874568,7.232,0.808,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv10.1 was tested at a top dose of 40 nM with an EC50 of 3.92 nM and a fold-to-NPS of 0.755. In the 2025-01-06 NPS IP1 experiment (plate AXN251223P1), NPSv10.1 was tested at a top dose of 5000 nM with an EC50 of 0.45 nM and a fold-to-NPS of 0.16."
NPSv10.1 Noah,In-house,,H-SFRNGVGTGMKK(D-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,1.88476672789066,1.88476672789066,8.725,1.779,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv10.2,In-house,N-Me-L-Thr13 (K12|T13 hardening),H-SFRNGVGTGMKK(N-Me-Thr))SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,0.4771085339171242,0.2047822818426889,9.321,1.028,"plates=5; Z'=0.603
lab notes: A January 2026 debrief reports NPSv10.2 assay results of FLIPR positive_fold 4.88x, IP1 positive_fold 0.76x, and cAMP positive_fold 23.20x relative to NPS. The note highlights that the large cAMP vs IP1 divergence in same-duration assays suggests genuine pathway selectivity for NPSv10.2 beyond degradation effects."
NPSv10.2,In-house,N-Me-L-Thr13 (K12|T13 hardening),H-SFRNGVGTGMKK(N-Me-Thr))SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,1.667536639375909,0.3142885476102624,8.778,1.505,"plates=5; Z'=0.603
lab notes: A January 2026 debrief reports NPSv10.2 assay results of FLIPR positive_fold 4.88x, IP1 positive_fold 0.76x, and cAMP positive_fold 23.20x relative to NPS. The note highlights that the large cAMP vs IP1 divergence in same-duration assays suggests genuine pathway selectivity for NPSv10.2 beyond degradation effects."
NPSv10.2,In-house,N-Me-L-Thr13 (K12|T13 hardening),H-SFRNGVGTGMKK(N-Me-Thr))SFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,18.62650521971362,1.320540677818104,7.73,1.407,"plates=5; Z'=0.603
lab notes: A January 2026 debrief reports NPSv10.2 assay results of FLIPR positive_fold 4.88x, IP1 positive_fold 0.76x, and cAMP positive_fold 23.20x relative to NPS. The note highlights that the large cAMP vs IP1 divergence in same-duration assays suggests genuine pathway selectivity for NPSv10.2 beyond degradation effects."
NPSv10.2,In-house,N-Me-L-Thr13 (K12|T13 hardening),H-SFRNGVGTGMKK(N-Me-Thr))SFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,13.21969527179496,0.06456828036422321,7.879,0.719,"plates=5; Z'=0.603
lab notes: A January 2026 debrief reports NPSv10.2 assay results of FLIPR positive_fold 4.88x, IP1 positive_fold 0.76x, and cAMP positive_fold 23.20x relative to NPS. The note highlights that the large cAMP vs IP1 divergence in same-duration assays suggests genuine pathway selectivity for NPSv10.2 beyond degradation effects."
NPSv10.3,In-house,D-Lys12 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,3.544421081122898,0.6826178953663784,8.45,1.728,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv10.3 was tested at a 40 nM top dose with EC50 3.54 nM and fold-to-NPS 0.683. In the 2025-01-06 NPS IP1 assay (plate AXN251223P1), NPSv10.3 had a 5000 nM top dose with EC50 0.71 nM and folds-to-NPS 0.24, and existing D-scan notes say it was well-tolerated with ~2× potency drop."
NPSv10.3,In-house,D-Lys12 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.895017610088285,0.6863647935581024,8.722,0.797,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv10.3 was tested at a 40 nM top dose with EC50 3.54 nM and fold-to-NPS 0.683. In the 2025-01-06 NPS IP1 assay (plate AXN251223P1), NPSv10.3 had a 5000 nM top dose with EC50 0.71 nM and folds-to-NPS 0.24, and existing D-scan notes say it was well-tolerated with ~2× potency drop."
NPSv10.3,In-house,D-Lys12 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)TSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.7110723767140048,,9.148,0.633,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv10.3 was tested at a 40 nM top dose with EC50 3.54 nM and fold-to-NPS 0.683. In the 2025-01-06 NPS IP1 assay (plate AXN251223P1), NPSv10.3 had a 5000 nM top dose with EC50 0.71 nM and folds-to-NPS 0.24, and existing D-scan notes say it was well-tolerated with ~2× potency drop."
NPSv10.3,In-house,D-Lys12 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,12.4224960537663,0.2430946589627526,7.906,0.777,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv10.3 was tested at a 40 nM top dose with EC50 3.54 nM and fold-to-NPS 0.683. In the 2025-01-06 NPS IP1 assay (plate AXN251223P1), NPSv10.3 had a 5000 nM top dose with EC50 0.71 nM and folds-to-NPS 0.24, and existing D-scan notes say it was well-tolerated with ~2× potency drop."
NPSv10.3,In-house,D-Lys12 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,46.76980093673755,0.2123020479986518,7.33,0.788,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR assay, NPSv10.3 was tested at a 40 nM top dose with EC50 3.54 nM and fold-to-NPS 0.683. In the 2025-01-06 NPS IP1 assay (plate AXN251223P1), NPSv10.3 had a 5000 nM top dose with EC50 0.71 nM and folds-to-NPS 0.24, and existing D-scan notes say it was well-tolerated with ~2× potency drop."
NPSv10.3 Noah,In-house,,H-SFRNGVGTGMK(D-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,4.088773371795069,4.088773371795069,8.388,1.506,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv10.4,In-house,N-Me-L-Lys12 (K12|T13 hardening),H-SFRNGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.207410604721913,0.4251238627458243,8.656,1.21,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv10.4 was tested at a top dose of 40 nM with EC50 2.21 nM and fold to NPS 0.425. On 2025-01-06 NPS IP1 (plate AXN251223P1), NPSv10.4 was tested at a top dose of 5000 nM with EC50 0,70 nM and folds to NPS 0,24."
NPSv10.4,In-house,N-Me-L-Lys12 (K12|T13 hardening),H-SFRNGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.940630835691614,0.7028856490942624,8.712,0.851,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv10.4 was tested at a top dose of 40 nM with EC50 2.21 nM and fold to NPS 0.425. On 2025-01-06 NPS IP1 (plate AXN251223P1), NPSv10.4 was tested at a top dose of 5000 nM with EC50 0,70 nM and folds to NPS 0,24."
NPSv10.4,In-house,N-Me-L-Lys12 (K12|T13 hardening),H-SFRNGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.7026596887304188,,9.153,0.86,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv10.4 was tested at a top dose of 40 nM with EC50 2.21 nM and fold to NPS 0.425. On 2025-01-06 NPS IP1 (plate AXN251223P1), NPSv10.4 was tested at a top dose of 5000 nM with EC50 0,70 nM and folds to NPS 0,24."
NPSv10.4,In-house,N-Me-L-Lys12 (K12|T13 hardening),H-SFRNGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,11.98109491581479,0.2344569215360976,7.922,0.949,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv10.4 was tested at a top dose of 40 nM with EC50 2.21 nM and fold to NPS 0.425. On 2025-01-06 NPS IP1 (plate AXN251223P1), NPSv10.4 was tested at a top dose of 5000 nM with EC50 0,70 nM and folds to NPS 0,24."
NPSv10.4,In-house,N-Me-L-Lys12 (K12|T13 hardening),H-SFRNGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,23.82999574326359,0.1081714439395884,7.623,0.632,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv10.4 was tested at a top dose of 40 nM with EC50 2.21 nM and fold to NPS 0.425. On 2025-01-06 NPS IP1 (plate AXN251223P1), NPSv10.4 was tested at a top dose of 5000 nM with EC50 0,70 nM and folds to NPS 0,24."
NPSv10.4 Noah,In-house,,H-SFRNGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.969808608348924,2.969808608348924,8.527,1.527,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv10.5,In-house,Orn12 (K12|T13 hardening),H-SFRNGVGTGMK(Orn)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.425883416702541,0.4671994084261204,8.615,1.745,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06, an NPS FLIPR experiment lists NPSv10.5 with a top dose of 40 nM, EC50 2.43 nM, and fold to NPS 0.467. On 2025-01-06, an NPS IP1 experiment (plate AXN251223P1) lists NPSv10.5 with a top dose of 5000 nM, EC50 0.65 nM, and folds to NPS 0.22."
NPSv10.5,In-house,Orn12 (K12|T13 hardening),H-SFRNGVGTGMK(Orn)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.756163499769917,0.636072610384712,8.755,0.99,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06, an NPS FLIPR experiment lists NPSv10.5 with a top dose of 40 nM, EC50 2.43 nM, and fold to NPS 0.467. On 2025-01-06, an NPS IP1 experiment (plate AXN251223P1) lists NPSv10.5 with a top dose of 5000 nM, EC50 0.65 nM, and folds to NPS 0.22."
NPSv10.5,In-house,Orn12 (K12|T13 hardening),H-SFRNGVGTGMK(Orn)TSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.6454448537181099,,9.19,0.958,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06, an NPS FLIPR experiment lists NPSv10.5 with a top dose of 40 nM, EC50 2.43 nM, and fold to NPS 0.467. On 2025-01-06, an NPS IP1 experiment (plate AXN251223P1) lists NPSv10.5 with a top dose of 5000 nM, EC50 0.65 nM, and folds to NPS 0.22."
NPSv10.5,In-house,Orn12 (K12|T13 hardening),H-SFRNGVGTGMK(Orn)TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,12.10503979923129,0.2368823873228367,7.917,1.036,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06, an NPS FLIPR experiment lists NPSv10.5 with a top dose of 40 nM, EC50 2.43 nM, and fold to NPS 0.467. On 2025-01-06, an NPS IP1 experiment (plate AXN251223P1) lists NPSv10.5 with a top dose of 5000 nM, EC50 0.65 nM, and folds to NPS 0.22."
NPSv10.5,In-house,Orn12 (K12|T13 hardening),H-SFRNGVGTGMK(Orn)TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,39.41671719576455,0.1789242121719456,7.404,0.866,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06, an NPS FLIPR experiment lists NPSv10.5 with a top dose of 40 nM, EC50 2.43 nM, and fold to NPS 0.467. On 2025-01-06, an NPS IP1 experiment (plate AXN251223P1) lists NPSv10.5 with a top dose of 5000 nM, EC50 0.65 nM, and folds to NPS 0.22."
NPSv10.5 Noah,In-house,,H-SFRNGVGTGMK(Orn)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,3.518530398792249,3.518530398792249,8.454,0.924,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv10.6,In-house,Dab12 (K12|T13 hardening),H-SFRNGVGTGMK(Dab)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,4.641086220717997,0.8938239660838339,8.333,0.967,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv10.6 had a top dose of 40 nM with EC50 4.64 nM and fold to NPS 0.894. On 2025-01-06 NPS IP1 (plate AXN251223P1), NPSv10.6 had a top dose of 5000 nM with EC50 0.47 nM and folds to NPS 0.16."
NPSv10.6,In-house,Dab12 (K12|T13 hardening),H-SFRNGVGTGMK(Dab)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.495247021611287,0.5415701193714954,8.825,0.99,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv10.6 had a top dose of 40 nM with EC50 4.64 nM and fold to NPS 0.894. On 2025-01-06 NPS IP1 (plate AXN251223P1), NPSv10.6 had a top dose of 5000 nM with EC50 0.47 nM and folds to NPS 0.16."
NPSv10.6,In-house,Dab12 (K12|T13 hardening),H-SFRNGVGTGMK(Dab)TSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.4733817654796991,,9.325,0.715,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv10.6 had a top dose of 40 nM with EC50 4.64 nM and fold to NPS 0.894. On 2025-01-06 NPS IP1 (plate AXN251223P1), NPSv10.6 had a top dose of 5000 nM with EC50 0.47 nM and folds to NPS 0.16."
NPSv10.6,In-house,Dab12 (K12|T13 hardening),H-SFRNGVGTGMK(Dab)TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,22.1650819825992,0.4337464082999478,7.654,1.068,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv10.6 had a top dose of 40 nM with EC50 4.64 nM and fold to NPS 0.894. On 2025-01-06 NPS IP1 (plate AXN251223P1), NPSv10.6 had a top dose of 5000 nM with EC50 0.47 nM and folds to NPS 0.16."
NPSv10.6,In-house,Dab12 (K12|T13 hardening),H-SFRNGVGTGMK(Dab)TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,38.34818149261838,0.1740738105539344,7.416,0.891,"plates=3-4; Z'=0.539
lab notes: On 2025-01-06 NPS FLIPR, NPSv10.6 had a top dose of 40 nM with EC50 4.64 nM and fold to NPS 0.894. On 2025-01-06 NPS IP1 (plate AXN251223P1), NPSv10.6 had a top dose of 5000 nM with EC50 0.47 nM and folds to NPS 0.16."
NPSv10.6 Noah,In-house,,H-SFRNGVGTGMK(Dab)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,3.38617753870377,3.38617753870377,8.47,1.06,"Z'=0.505; 0.619; 0.668; plate_instance=1
lab notes: On 2025-01-06 NPS FLIPR, NPSv10.6 was tested at a 40 nM top dose with EC50 4.64 nM and fold-to-NPS 0.894. On 2025-01-06 NPS IP1 (plate AXN251223P1), NPSv10.6 had a 5000 nM top dose with EC50 0.47 nM and fold-to-NPS 0.16."
NPSv10.7,In-house,Nle12 (K12|T13 hardening),H-SFRNGVGTGMK(Nle)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,3.931388276722625,0.7571436716752223,8.405,2.261,"plates=3-4; Z'=0.539
lab notes: 2025-01-06 NPS FLIPR lists NPSv10.7 with a top dose of 40 nM, EC50 3.93 nM, and fold to NPS 0.757. The 2025-01-06 NPS IP1 table (plate AXN251223P1) lists NPSv10.7 with a top dose of 5000 nM, EC50 0.67, and folds to NPS 0.23."
NPSv10.7,In-house,Nle12 (K12|T13 hardening),H-SFRNGVGTGMK(Nle)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,2.159184694888505,0.7820446361403048,8.666,1.15,"plates=3-4; Z'=0.539
lab notes: 2025-01-06 NPS FLIPR lists NPSv10.7 with a top dose of 40 nM, EC50 3.93 nM, and fold to NPS 0.757. The 2025-01-06 NPS IP1 table (plate AXN251223P1) lists NPSv10.7 with a top dose of 5000 nM, EC50 0.67, and folds to NPS 0.23."
NPSv10.7,In-house,Nle12 (K12|T13 hardening),H-SFRNGVGTGMK(Nle)TSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.6677556833697395,,9.175,1.274,"plates=3-4; Z'=0.539
lab notes: 2025-01-06 NPS FLIPR lists NPSv10.7 with a top dose of 40 nM, EC50 3.93 nM, and fold to NPS 0.757. The 2025-01-06 NPS IP1 table (plate AXN251223P1) lists NPSv10.7 with a top dose of 5000 nM, EC50 0.67, and folds to NPS 0.23."
NPSv10.7,In-house,Nle12 (K12|T13 hardening),H-SFRNGVGTGMK(Nle)TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,16.52096503457113,0.3232972136543362,7.782,1.196,"plates=3-4; Z'=0.539
lab notes: 2025-01-06 NPS FLIPR lists NPSv10.7 with a top dose of 40 nM, EC50 3.93 nM, and fold to NPS 0.757. The 2025-01-06 NPS IP1 table (plate AXN251223P1) lists NPSv10.7 with a top dose of 5000 nM, EC50 0.67, and folds to NPS 0.23."
NPSv10.7,In-house,Nle12 (K12|T13 hardening),H-SFRNGVGTGMK(Nle)TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,51.21067085523941,0.2324604784326154,7.291,0.913,"plates=3-4; Z'=0.539
lab notes: 2025-01-06 NPS FLIPR lists NPSv10.7 with a top dose of 40 nM, EC50 3.93 nM, and fold to NPS 0.757. The 2025-01-06 NPS IP1 table (plate AXN251223P1) lists NPSv10.7 with a top dose of 5000 nM, EC50 0.67, and folds to NPS 0.23."
NPSv10.7 Noah,In-house,,H-SFRNGVGTGMK(Nle)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,3.892347248695628,3.892347248695628,8.41,1.437,"Z'=0.505; 0.619; 0.668; plate_instance=1
lab notes: On 2025-01-06, NPSv10.7 was tested in the NPS FLIPR assay with a top dose of 40 nM and an EC50 of 3.93 nM. The same date’s NPS IP1 assay (plate AXN251223P1) lists NPSv10.7 at a top dose of 5000 nM with an EC50 of 0.67 nM."
NPSv10.11,In-house,D-Lys12 + D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)(D-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.649568869489941,0.5102788534218139,8.577,1.23,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR experiment, NPSv10.11 had a top dose of 40 nM with EC50 2.65 nM and fold to NPS 0.510. In the 20250106 NPS IP1 experiment (plate AXN251223P1), NPSv10.11 had a top dose of 5000 nM with EC50 0,69 nM and folds to NPS 0,23."
NPSv10.11,In-house,D-Lys12 + D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)(D-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.516247844224603,0.5491765000197827,8.819,0.947,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR experiment, NPSv10.11 had a top dose of 40 nM with EC50 2.65 nM and fold to NPS 0.510. In the 20250106 NPS IP1 experiment (plate AXN251223P1), NPSv10.11 had a top dose of 5000 nM with EC50 0,69 nM and folds to NPS 0,23."
NPSv10.11,In-house,D-Lys12 + D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)(D-Thr)SFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.6852281336117709,,9.164,1.062,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR experiment, NPSv10.11 had a top dose of 40 nM with EC50 2.65 nM and fold to NPS 0.510. In the 20250106 NPS IP1 experiment (plate AXN251223P1), NPSv10.11 had a top dose of 5000 nM with EC50 0,69 nM and folds to NPS 0,23."
NPSv10.11,In-house,D-Lys12 + D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)(D-Thr)SFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,17.5269618722794,0.3429834713212207,7.756,0.934,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR experiment, NPSv10.11 had a top dose of 40 nM with EC50 2.65 nM and fold to NPS 0.510. In the 20250106 NPS IP1 experiment (plate AXN251223P1), NPSv10.11 had a top dose of 5000 nM with EC50 0,69 nM and folds to NPS 0,23."
NPSv10.11,In-house,D-Lys12 + D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)(D-Thr)SFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,52.42377224872516,0.2379671067506492,7.28,0.822,"plates=3-4; Z'=0.539
lab notes: In the 20250106 NPS FLIPR experiment, NPSv10.11 had a top dose of 40 nM with EC50 2.65 nM and fold to NPS 0.510. In the 20250106 NPS IP1 experiment (plate AXN251223P1), NPSv10.11 had a top dose of 5000 nM with EC50 0,69 nM and folds to NPS 0,23."
NPSv10.11 Noah,In-house,,H-SFRNGVGTGMK(D-Lys)(D-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,4.012063187033577,4.012063187033577,8.397,1.531,"Z'=0.505; 0.619; 0.668; plate_instance=1
lab notes: In the 20250106 NPS FLIPR assay, NPSv10.11 was tested at a 40 nM top dose with EC50 2.65 nM and fold-to-NPS 0.510. In the 20250106 NPS IP1 assay (plate AXN251223P1), NPSv10.11 was tested at a 5000 nM top dose with EC50 0.69 nM and fold-to-NPS 0.23."
NPSv10.13,In-house,N-Me-Lys12 + D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(N-Me-Lys)(D-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,3.552498793179163,0.6841735770071943,8.449,1.522,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv10.13 had a top dose of 40 nM, an EC50 of 3.55 nM, and a fold to NPS of 0.684. In the 2025-01-06 NPS IP1 experiment (plate AXN251223P1), NPSv10.13 had a top dose of 5000 nM, an EC50 of 0.41 nM, and a fold to NPS of 0.14."
NPSv10.13,In-house,N-Me-Lys12 + D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(N-Me-Lys)(D-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.54117770360638,0.5582059558395669,8.812,1.156,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv10.13 had a top dose of 40 nM, an EC50 of 3.55 nM, and a fold to NPS of 0.684. In the 2025-01-06 NPS IP1 experiment (plate AXN251223P1), NPSv10.13 had a top dose of 5000 nM, an EC50 of 0.41 nM, and a fold to NPS of 0.14."
NPSv10.13,In-house,N-Me-Lys12 + D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(N-Me-Lys)(D-Thr)SFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.4106273238042549,,9.387,1.186,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv10.13 had a top dose of 40 nM, an EC50 of 3.55 nM, and a fold to NPS of 0.684. In the 2025-01-06 NPS IP1 experiment (plate AXN251223P1), NPSv10.13 had a top dose of 5000 nM, an EC50 of 0.41 nM, and a fold to NPS of 0.14."
NPSv10.13,In-house,N-Me-Lys12 + D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(N-Me-Lys)(D-Thr)SFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,13.68087664593175,0.2677197906250052,7.864,1.35,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv10.13 had a top dose of 40 nM, an EC50 of 3.55 nM, and a fold to NPS of 0.684. In the 2025-01-06 NPS IP1 experiment (plate AXN251223P1), NPSv10.13 had a top dose of 5000 nM, an EC50 of 0.41 nM, and a fold to NPS of 0.14."
NPSv10.13,In-house,N-Me-Lys12 + D-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(N-Me-Lys)(D-Thr)SFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,33.00248826489626,0.149808117788788,7.481,0.926,"plates=3-4; Z'=0.539
lab notes: In the 2025-01-06 NPS FLIPR experiment, NPSv10.13 had a top dose of 40 nM, an EC50 of 3.55 nM, and a fold to NPS of 0.684. In the 2025-01-06 NPS IP1 experiment (plate AXN251223P1), NPSv10.13 had a top dose of 5000 nM, an EC50 of 0.41 nM, and a fold to NPS of 0.14."
NPSv10.13 Noah,In-house,,H-SFRNGVGTGMK(N-Me-Lys)(D-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.446219702542068,2.446219702542068,8.612,1.248,"Z'=0.505; 0.619; 0.668; plate_instance=1
lab notes: In the 20250106 NPS FLIPR experiment, NPSv10.13 is listed with top dose 40 nM, EC50 3.55 nM, and fold to NPS 0.684. In the 20250106 NPS IP1 experiment (plate AXN251223P1), NPSv10.13 is listed with top dose 5000 nM, EC50 0,41 nM, and folds to NPS 0,14."
NPSv10.14,In-house,D-Lys12 + N-Me-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)(N-Me-Thr)SFQRAKS-NH₂,Ca2+/FLIPR,hNPSR-Ile107,HEK293,2.703148004134905,2.703148004134905,8.568,1.909,"plates=5; Z'=0.603
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv10.14 (top dose 40 nM) showed EC50 2.70 nM with fold to NPS 0.340; in the 2025-01-06 NPS IP1 assay (plate AXN251223P3, top dose 5000 nM) it showed EC50 0.53 nM with folds to NPS 0.18. A separate note dated 2026-01-06 states NPSv10.14 “performed really well.”"
NPSv10.14,In-house,D-Lys12 + N-Me-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)(N-Me-Thr)SFQRAKS-NH₂,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.918761740878703,0.6871292625371412,8.717,1.079,"plates=5; Z'=0.603
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv10.14 (top dose 40 nM) showed EC50 2.70 nM with fold to NPS 0.340; in the 2025-01-06 NPS IP1 assay (plate AXN251223P3, top dose 5000 nM) it showed EC50 0.53 nM with folds to NPS 0.18. A separate note dated 2026-01-06 states NPSv10.14 “performed really well.”"
NPSv10.14,In-house,D-Lys12 + N-Me-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)(N-Me-Thr)SFQRAKS-NH₂,IP1,hNPSR-Ile107,HEK293,0.532144454645357,,9.274,1.519,"plates=5; Z'=0.603
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv10.14 (top dose 40 nM) showed EC50 2.70 nM with fold to NPS 0.340; in the 2025-01-06 NPS IP1 assay (plate AXN251223P3, top dose 5000 nM) it showed EC50 0.53 nM with folds to NPS 0.18. A separate note dated 2026-01-06 states NPSv10.14 “performed really well.”"
NPSv10.14,In-house,D-Lys12 + N-Me-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)(N-Me-Thr)SFQRAKS-NH₂,IP1,hNPSR-Asn107,HEK293,15.55220786648437,0.518757528242108,7.808,0.892,"plates=5; Z'=0.603
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv10.14 (top dose 40 nM) showed EC50 2.70 nM with fold to NPS 0.340; in the 2025-01-06 NPS IP1 assay (plate AXN251223P3, top dose 5000 nM) it showed EC50 0.53 nM with folds to NPS 0.18. A separate note dated 2026-01-06 states NPSv10.14 “performed really well.”"
NPSv10.14,In-house,D-Lys12 + N-Me-Thr13 (K12|T13 hardening),H-SFRNGVGTGMK(D-Lys)(N-Me-Thr)SFQRAKS-NH₂,cAMP,hNPSR-Asn107,HEK293,46.16569346435995,0.2254847314956938,7.336,0.809,"plates=5; Z'=0.603
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv10.14 (top dose 40 nM) showed EC50 2.70 nM with fold to NPS 0.340; in the 2025-01-06 NPS IP1 assay (plate AXN251223P3, top dose 5000 nM) it showed EC50 0.53 nM with folds to NPS 0.18. A separate note dated 2026-01-06 states NPSv10.14 “performed really well.”"
NPSv10.14 ChinaPeptides,In-house,,H-SFRNGVGTGMK(D-Lys)(N-Me-Thr)SFQRAKS-NH₂,Ca2+/FLIPR,hNPSR-Ile107,HEK293,,1000,,-1.003,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv10.15,In-house,"N,N,N-trimethyl-Lys12 (K12|T13 hardening)",H-SFRNGVGTGMK[Lys(Me3)]TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,1.890321459913516,0.3640558576418541,8.723,7.787,"plates=3-4; Z'=0.539
lab notes: On January 6, 2025 (NPS FLIPR), NPSv10.15 was tested at a top dose of 40 nM with EC50 1.89 nM and fold to NPS 0.364. On January 6, 2025 (NPS IP1, plate AXN251223P1), NPSv10.15 was tested at a top dose of 5000 nM with EC50 0.57 nM and fold to NPS 0.19."
NPSv10.15,In-house,"N,N,N-trimethyl-Lys12 (K12|T13 hardening)",H-SFRNGVGTGMK[Lys(Me3)]TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,1.409722453606308,0.5105935985463678,8.851,1.677,"plates=3-4; Z'=0.539
lab notes: On January 6, 2025 (NPS FLIPR), NPSv10.15 was tested at a top dose of 40 nM with EC50 1.89 nM and fold to NPS 0.364. On January 6, 2025 (NPS IP1, plate AXN251223P1), NPSv10.15 was tested at a top dose of 5000 nM with EC50 0.57 nM and fold to NPS 0.19."
NPSv10.15,In-house,"N,N,N-trimethyl-Lys12 (K12|T13 hardening)",H-SFRNGVGTGMK[Lys(Me3)]TSFQRAKS-NH2,IP1,hNPSR-Ile107,HEK293,0.5670440126741239,,9.246,1.393,"plates=3-4; Z'=0.539
lab notes: On January 6, 2025 (NPS FLIPR), NPSv10.15 was tested at a top dose of 40 nM with EC50 1.89 nM and fold to NPS 0.364. On January 6, 2025 (NPS IP1, plate AXN251223P1), NPSv10.15 was tested at a top dose of 5000 nM with EC50 0.57 nM and fold to NPS 0.19."
NPSv10.15,In-house,"N,N,N-trimethyl-Lys12 (K12|T13 hardening)",H-SFRNGVGTGMK[Lys(Me3)]TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,14.74160410835014,0.2884770667483367,7.831,1.17,"plates=3-4; Z'=0.539
lab notes: On January 6, 2025 (NPS FLIPR), NPSv10.15 was tested at a top dose of 40 nM with EC50 1.89 nM and fold to NPS 0.364. On January 6, 2025 (NPS IP1, plate AXN251223P1), NPSv10.15 was tested at a top dose of 5000 nM with EC50 0.57 nM and fold to NPS 0.19."
NPSv10.15,In-house,"N,N,N-trimethyl-Lys12 (K12|T13 hardening)",H-SFRNGVGTGMK[Lys(Me3)]TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,30.13205371615932,0.1367783609555863,7.521,0.829,"plates=3-4; Z'=0.539
lab notes: On January 6, 2025 (NPS FLIPR), NPSv10.15 was tested at a top dose of 40 nM with EC50 1.89 nM and fold to NPS 0.364. On January 6, 2025 (NPS IP1, plate AXN251223P1), NPSv10.15 was tested at a top dose of 5000 nM with EC50 0.57 nM and fold to NPS 0.19."
NPSv10.15 Noah,In-house,,H-SFRNGVGTGMK[Lys(Me3)]TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,5.073282995749738,5.073282995749738,8.295,1.112,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv11,In-house,Nle10 (Met10 oxidation protection),,Ca2+/FLIPR,hNPSR-Ile107,HEK293,9.198075929653715,1.771451836227993,8.036,5.675,"Z'=0.507; 0.555; 0.504; plate_instance=1
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv11 was tested at a top dose of 40 nM with an EC50 of 9.20 nM and a fold to NPS of 1.771. On 2025-01-06 in the NPS IP1 assay (plate AXN251223P1), NPSv11 was tested at a top dose of 5000 nM with an EC50 of 3.85 nM and a fold to NPS of 1.31."
NPSv11,In-house,Nle10 (Met10 oxidation protection),,IP1,hNPSR-Ile107,HEK293,3.846278668317985,,8.415,0.701,"Z'=0.507; 0.555; 0.504; plate_instance=1
lab notes: On 2025-01-06 in the NPS FLIPR assay, NPSv11 was tested at a top dose of 40 nM with an EC50 of 9.20 nM and a fold to NPS of 1.771. On 2025-01-06 in the NPS IP1 assay (plate AXN251223P1), NPSv11 was tested at a top dose of 5000 nM with an EC50 of 3.85 nM and a fold to NPS of 1.31."
NPSv11 Noah,In-house,,,Ca2+/FLIPR,hNPSR-Ile107,HEK293,10.1733855687638,10.1733855687638,7.993,1.434,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv14,In-house,D-Ser1 + β-hArg3 + Nle10 + N-Me-K11 + C16-palm-K12 + C-term amide (combo),H-(D-Ser)F(β-hArg)NGVGTG(Nle)(N-Me-K)K(γ-E-C16)TSFQRAKS-NH₂,Ca2+/FLIPR,hNPSR-Ile107,HEK293,40,7.703575616361252,7.398,7.26,"Z'=0.507; 0.555; 0.504; plate_instance=1
lab notes: 2025-01-06 NPS FLIPR lists NPSv14 with a top dose of 40 nM, EC50 40.00 nM, and fold to NPS 7.704. lab notes: 2025-01-06 NPS IP1 (plate AXN251223P1) lists NPSv14 with a top dose of 5000 nM, EC50 75,10 nM, and folds to NPS 25,60."
NPSv14,In-house,D-Ser1 + β-hArg3 + Nle10 + N-Me-K11 + C16-palm-K12 + C-term amide (combo),H-(D-Ser)F(β-hArg)NGVGTG(Nle)(N-Me-K)K(γ-E-C16)TSFQRAKS-NH₂,IP1,hNPSR-Ile107,HEK293,75.09605729290216,,7.124,1.036,"Z'=0.507; 0.555; 0.504; plate_instance=1
lab notes: 2025-01-06 NPS FLIPR lists NPSv14 with a top dose of 40 nM, EC50 40.00 nM, and fold to NPS 7.704. lab notes: 2025-01-06 NPS IP1 (plate AXN251223P1) lists NPSv14 with a top dose of 5000 nM, EC50 75,10 nM, and folds to NPS 25,60."
NPSv14 Noah,In-house,,H-(D-Ser)F(β-hArg)NGVGTG(Nle)(N-Me-K)K(γ-E-C16)TSFQRAKS-NH₂,Ca2+/FLIPR,hNPSR-Ile107,HEK293,60.01508107765159,60.01508107765159,7.222,1.466,Z'=0.505; 0.619; 0.668; plate_instance=1
NPSv15.1,In-house,"D-Ser1 + β-hAsn4 + Nle10 + D-Lys12 + N-Me-Thr13, C-term amide",H-(D-Ser)FR(β-hAsn)GVGTG(Nle)K(D-Lys)(N-Me-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,268.2089875234498,115.1194006630574,6.572,1.222,"plates=5; Z'=0.603
lab notes: NPSv15.1 includes a note that Nle was retained and this yielded only about a 30% hit in efficacy."
NPSv15.1,In-house,"D-Ser1 + β-hAsn4 + Nle10 + D-Lys12 + N-Me-Thr13, C-term amide",H-(D-Ser)FR(β-hAsn)GVGTG(Nle)K(D-Lys)(N-Me-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,11.72076556142442,2.209068333610422,7.931,38.099,"plates=5; Z'=0.603
lab notes: NPSv15.1 includes a note that Nle was retained and this yielded only about a 30% hit in efficacy."
NPSv15.1,In-house,"D-Ser1 + β-hAsn4 + Nle10 + D-Lys12 + N-Me-Thr13, C-term amide",H-(D-Ser)FR(β-hAsn)GVGTG(Nle)K(D-Lys)(N-Me-Thr)SFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,354.4789165335458,,49.666,"plates=5; Z'=0.603
lab notes: NPSv15.1 includes a note that Nle was retained and this yielded only about a 30% hit in efficacy."
NPSv15.1,In-house,"D-Ser1 + β-hAsn4 + Nle10 + D-Lys12 + N-Me-Thr13, C-term amide",H-(D-Ser)FR(β-hAsn)GVGTG(Nle)K(D-Lys)(N-Me-Thr)SFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,24.42124384742197,,6.764,"plates=5; Z'=0.603
lab notes: NPSv15.1 includes a note that Nle was retained and this yielded only about a 30% hit in efficacy."
NPSv15.2,In-house,"D-Ser1 + β-hAsn4 + Nle10 + N-Me-Lys12 + D-Thr13, C-term amide",H-(D-Ser)FR(β-hAsn)GVGTG(Nle)K(N-Me-Lys)(D-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,100.4333565575466,43.1075331227409,6.998,2.604,20260128 new experiment; receptor=107N
NPSv15.2,In-house,"D-Ser1 + β-hAsn4 + Nle10 + N-Me-Lys12 + D-Thr13, C-term amide",H-(D-Ser)FR(β-hAsn)GVGTG(Nle)K(N-Me-Lys)(D-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,57.24969790171955,10.79012237559694,7.242,2.569,20260128 new experiment; receptor=107I
NPSv15.2,In-house,"D-Ser1 + β-hAsn4 + Nle10 + N-Me-Lys12 + D-Thr13, C-term amide",H-(D-Ser)FR(β-hAsn)GVGTG(Nle)K(N-Me-Lys)(D-Thr)SFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,354.4789165335458,,-0.001,20260128 new experiment; receptor=107N
NPSv15.2,In-house,"D-Ser1 + β-hAsn4 + Nle10 + N-Me-Lys12 + D-Thr13, C-term amide",H-(D-Ser)FR(β-hAsn)GVGTG(Nle)K(N-Me-Lys)(D-Thr)SFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,24.42124384742197,,0.285,plates=5; Z'=0.603
NPSv16.1,In-house,β-hArg3 + N-Me-Lys12,H-SF(beta-homo-Arg)NGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,6.592493237934091,2.829598953539459,8.181,1.985,"plates=5; Z'=0.603
lab notes: In Study 1586, NPSv16.1 was given intranasally at 100 ug/mouse; notes report clear sedation (350 cm at H7, 47% inactive vs ~25% baseline). Assay notes report 107I FLIPR Emax 114% (super-agonist) and 107N partial agonist 84%, with stability data not yet available."
NPSv16.1,In-house,β-hArg3 + N-Me-Lys12,H-SF(beta-homo-Arg)NGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,12.25239345576865,2.309266766938449,7.912,1.501,"plates=5; Z'=0.603
lab notes: In Study 1586, NPSv16.1 was given intranasally at 100 ug/mouse; notes report clear sedation (350 cm at H7, 47% inactive vs ~25% baseline). Assay notes report 107I FLIPR Emax 114% (super-agonist) and 107N partial agonist 84%, with stability data not yet available."
NPSv16.1,In-house,β-hArg3 + N-Me-Lys12,H-SF(beta-homo-Arg)NGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,599.6871754930133,42.51529204556514,6.222,1.377,"plates=5; Z'=0.603
lab notes: In Study 1586, NPSv16.1 was given intranasally at 100 ug/mouse; notes report clear sedation (350 cm at H7, 47% inactive vs ~25% baseline). Assay notes report 107I FLIPR Emax 114% (super-agonist) and 107N partial agonist 84%, with stability data not yet available."
NPSv16.1,In-house,β-hArg3 + N-Me-Lys12,H-SF(beta-homo-Arg)NGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,725.0067170778374,3.541113165755347,6.14,1.004,"plates=5; Z'=0.603
lab notes: In Study 1586, NPSv16.1 was given intranasally at 100 ug/mouse; notes report clear sedation (350 cm at H7, 47% inactive vs ~25% baseline). Assay notes report 107I FLIPR Emax 114% (super-agonist) and 107N partial agonist 84%, with stability data not yet available."
NPSv16.2,In-house,β-hArg3 + N-Me-Lys12 + N-Me-Thr13,H-SF(beta-homo-Arg)NGVGTGMK(N-Me-Lys)(N-Me-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,13.03620596661215,5.595339036374961,7.885,1.123,20260128 new experiment; receptor=107N
NPSv16.2,In-house,β-hArg3 + N-Me-Lys12 + N-Me-Thr13,H-SF(beta-homo-Arg)NGVGTGMK(N-Me-Lys)(N-Me-Thr)SFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,14.78489057414061,2.786578522713833,7.83,1.663,20260128 new experiment; receptor=107I
NPSv16.2,In-house,β-hArg3 + N-Me-Lys12 + N-Me-Thr13,H-SF(beta-homo-Arg)NGVGTGMK(N-Me-Lys)(N-Me-Thr)SFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,538.1348183609745,38.15148947231494,6.269,1.643,20260128 new experiment; receptor=107N
NPSv16.2,In-house,β-hArg3 + N-Me-Lys12 + N-Me-Thr13,H-SF(beta-homo-Arg)NGVGTGMK(N-Me-Lys)(N-Me-Thr)SFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,548.1095070175169,2.677103185193004,6.261,1.299,plates=5; Z'=0.603
NPSv16.3,In-house,β-hAsn4 + N-Me-Lys12 (corrected: R retained),H-SFR(beta-homo-Asn)GVGTGMK(N-Me-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,,429.2152985849976,,1.318,20260128 new experiment; receptor=107N
NPSv16.3,In-house,β-hAsn4 + N-Me-Lys12 (corrected: R retained),H-SFR(beta-homo-Asn)GVGTGMK(N-Me-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,,188.4747478339593,,17.175,20260128 new experiment; receptor=107I
NPSv16.3,In-house,β-hAsn4 + N-Me-Lys12 (corrected: R retained),H-SFR(beta-homo-Asn)GVGTGMK(N-Me-Lys)TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,,354.4789165335458,,6.443,20260128 new experiment; receptor=107N
NPSv16.3,In-house,β-hAsn4 + N-Me-Lys12 (corrected: R retained),H-SFR(beta-homo-Asn)GVGTGMK(N-Me-Lys)TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,,24.42124384742197,,-1.007,plates=5; Z'=0.603
NPSv16.5,In-house,hArg3 + N-Me-Lys12,H-SF(hArg)NGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Asn107,HEK293,10.81666122944832,4.642676479290427,7.966,1.092,20260128 new experiment; receptor=107N
NPSv16.5,In-house,hArg3 + N-Me-Lys12,H-SF(hArg)NGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,Ca2+/FLIPR,hNPSR-Ile107,HEK293,12.72822545889631,2.398949083739262,7.895,1.621,20260128 new experiment; receptor=107I
NPSv16.5,In-house,hArg3 + N-Me-Lys12,H-SF(hArg)NGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,IP1,hNPSR-Asn107,HEK293,881.8599488827001,62.52015184285352,6.055,1.347,20260128 new experiment; receptor=107N
NPSv16.5,In-house,hArg3 + N-Me-Lys12,H-SF(hArg)NGVGTGMK(N-Me-Lys)TSFQRAKS-NH2,cAMP,hNPSR-Asn107,HEK293,851.167462649029,4.157313632068673,6.07,0.911,plates=5; Z'=0.603
